Compounds and drugs that inhibit the binding of CUG repeat RNA to MBNL protein

By developing compounds with specific structures to inhibit the binding of CUG repeat RNA to MBNL protein, the problem of difficult DM1 treatment in existing technologies has been solved, providing a new treatment approach.

CN123076592APending Publication Date: 2026-11-10NIPPON SHINYAKU CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580025651.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-05
Filing Date
2025-04-07
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current technology does not have an effective compound that can sufficiently inhibit the binding of CUG repeat RNA to MBNL protein, making the treatment of DM1 amyotrophic lateral sclerosis difficult.

Method used

A series of compounds or their pharmaceutically acceptable salts or solvates have been developed to inhibit the binding of CUG repeat RNA to MBNL protein by compounds with specific structures such as those shown in general formula (1), including specific substituted or unsubstituted nitrogen-containing heterocyclic groups, alkylene groups, etc.

Benefits of technology

These compounds can effectively inhibit the binding of CUG repetitive RNA to MBNL protein, potentially improving DM1 splicing abnormalities and providing new treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123076592A_ABST
    Figure CN123076592A_ABST
Patent Text Reader

Abstract

The compound represented by general formula (1) or its pharmaceutically acceptable salt or solvate thereof: [Chemical 1] where X 1 X 2 and X 3 The symbols are -CH=, etc., A represents -O-, etc., B represents a single bond, C1 to C5 alkylene groups, etc., and C represents a substituted or unsubstituted nitrogen-containing heterocyclic group, etc., wherein at least one of B and C contains more than one nitrogen atom.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to compounds and drugs having binding inhibitory activity between CUG repeat RNA and MBNL protein. Background Technology

[0002] Myotonic dystrophy type 1 (hereinafter sometimes abbreviated as "DM1") is the most common muscular atrophy in adults. DM1 is an autosomal dominant disease affecting skeletal muscle, smooth muscle, eyes, heart, endocrine system, and central nervous system. The main symptoms are muscle atrophy, muscle weakness, myotonia, cataracts, insulin resistance, cardiac conduction disorders, and intellectual disability (Non-Patent Literature 1). The MBNL (Muscleblind-like) protein, a splicing regulator, binds to the CUG repeat sequence in the abnormal DMPK mRNA, which is caused by the abnormal expansion of the CTG repeat sequence in the 3' untranslated region of the myotonic protein kinase (DMPK) gene. As a result, there is insufficient splicing regulator required for normal splicing, leading to splicing abnormalities and causing symptoms.

[0003] The CUG repeat RNA and MBNL protein of abnormal DMPK are believed to be expressed in a wide range of tissues throughout the body, including skeletal muscle, smooth muscle, eyes, heart, endocrine system, and central nervous system. Abnormal gene splicing in these tissues is associated with symptoms. It has been reported that CLCN1 (chloride channel protein, skeletal muscle), a chloride ion channel, is associated with myotonia; CACNA1S (voltage-gated calcium channel subunit alpha 1S) or DMD (dystrophin), a calcium ion channel, is associated with muscle weakness; INSR (insulin-like growth factor receptor) is associated with insulin resistance; and NMDA (N-methyl-D-aspartate) or MAPT (microtubule-associated protein tau) is associated with cognitive function (Non-Patent Literature 2-4). Therefore, it is assumed that improving splicing abnormalities can treat DM1.

[0004] Current treatments for DM1 are mostly limited to symptomatic relief, making treatment extremely difficult. It has been shown that dissociating CUG repeat RNA and MBNL protein, which are abnormally bound in DM1, can improve splicing and muscle rigidity symptoms (Non-Patent Literature 5-6). However, no drugs have yet demonstrated sufficient efficacy in clinical trials to achieve approval. Therefore, compounds that inhibit the binding of CUG repeat RNA to MBNL protein are being considered as a potential novel treatment approach.

[0005] Existing technical documents Non-patent literature Non-patent literature 1: Meola G and Cardani R. Biochim Biophys Acta. 2015 Apr; 1852(4): 594-606. Non-patent literature 2: N Charlet-B et al., Mol Cell. 2002 Jul;10(1):45-53. Non-patent literature 3: Nakamori et al., Ann Neurol. 2013 Dec; 74(6): 862-72. Non-patent literature 4: A Lopez-Martinez et al., Genes (Basel). 2020 Sep 22; 11(9): 1109. Non-patent literature 5: AJ Angelbello et al., Cell Chem Biol. 2021 Jan 21; 28(1): 34-45. Non-patent literature 6: Nakamori et al., Ann Clin Transl Neurol. 2015 Dec 10; 3(1): 42-54. Non-patent literature 7: A Mankodi et al., Science, 2000, 289 (5485), 1769-73 Non-patent literature 8: Jenquin JR et al., ACS Chem Biol. 2018 Sep 21;13(9):2708-2718. Summary of the Invention

[0006] The problem that the invention aims to solve The purpose of this invention is to provide a compound or a pharmaceutically acceptable salt thereof, or a solvate thereof, having binding inhibitory activity that inhibits the binding of CUG repeat RNA to MBNL protein.

[0007] Methods for solving problems This invention includes, for example, the inventions shown below.

[0008] [1] The compound represented by general formula (1) or its pharmaceutically acceptable salt or solvate thereof: [Chemistry 1] In the formula, X 1 X 2 and X 3 For any of the following combinations: (a) X 1 X 2 and X 3 -CH=; (b)X 1 For -N=, X 2 -CH=, X 3 -CH=; or (c)X 1 -CH=, X 2 -CH=, X 3 For -N=, A represents -O-, -S-, -NR-, or piperidinediyl, where R represents a hydrogen atom or a C1-C3 alkyl group. B represents a single bond, a C1-C5 alkylene group that can be substituted with a hydroxyl group, or -Y. 1 -NY 2 -Y 3 -, Y 1 and Y 3 Each independently represents a C1-C3 alkylene group, Y 2 Indicates a hydrogen atom or a C1-C3 alkyl group. C represents a substituted or unsubstituted aryl group, a substituted or unsubstituted nitrogen-containing heterocyclic group, or a dialkylamino group. In this case, at least one of B and C contains more than one nitrogen atom.

[0009] [2] According to the compound described in [1] or its pharmaceutically acceptable salt or its solvation, wherein A is -O-.

[0010] [3] The compound described in [1] or [2], or its pharmaceutically acceptable salt or solvation thereof, wherein B is a single bond or a C1-C5 alkylene group.

[0011] [4] The compound or a pharmaceutically acceptable salt thereof, or a solvate thereof, according to any one of [1] to [3], wherein C is a substituted or unsubstituted nitrogen-containing heterocyclic group.

[0012] [5] The compound or a pharmaceutically acceptable salt thereof, or a solvate thereof, according to any one of [1] to [4], wherein C is a substituted or unsubstituted piperidinyl, a substituted or unsubstituted piperazine, or a substituted or unsubstituted pyrrolidinyl.

[0013] [6] The compound or a pharmaceutically acceptable salt thereof, or a solvation thereof, according to any one of [1] to [5], wherein C is a nitrogen-containing heterocyclic group substituted with an alkyl, benzyl or acyl group, or an unsubstituted nitrogen-containing heterocyclic group.

[0014] [7] According to [1], the compound or its pharmaceutically acceptable salt, or its solvation, wherein X 1 X 2 and X 3 For (a)X 1 X 2 and X 3 For combinations of -CH=, A represents -O-, B represents a single bond or a C1-C5 alkylene bond. C represents a substituted or unsubstituted nitrogen-containing heterocyclic group.

[0015] [8] The compound or a pharmaceutically acceptable salt thereof, or a solvation thereof, wherein the compound is selected from the group consisting of (1) to (104) and (107) to (119): (1) 3-{5-[(1-ethylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (2) 3-(5-{[(3R)-1-ethylpiperidin-3-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (3) 3-(5-{[(3S)-1-ethylpiperidin-3-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (4) 3-{5-[(1-benzylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (5) 3-(5-{2-[benzyl(methyl)amino]ethoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (6) 3-{5-[2-(4-acetylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (7) 3-{5-[3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (8) 3-{5-[3-(pyrrolidone-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (9) 3-{5-[2-(pyrrolidone-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (10) 3-{5-[2-(4-benzylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (11) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid phenyl ester (12) 3-{5-[2-(piperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (13) 3-{5-[2-(4-phenoxypiperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (14) 3-{5-[(1-cyclopropanecarbonylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (15) 3-{5-[(1-propylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (16) 3-(5-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (17) 3-{5-[(1-propylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (18) 3-{5-[2-(2,3-dihydro-1H-isoindol-2-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (19) 3-{5-[2-(1,2,3,4-tetrahydroisoquinolin-2-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (20) 4-({[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}methyl)piperidine-1-carboxylic acid ethyl ester (21) 3-(5-{3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (22) 3-{5-[2-(4-phenylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (23) 3-{5-[3-(piperidin-1-yl)propoxy]pyrimidin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (24) 3-{6-[3-(piperidin-1-yl)propoxy]pyridazin-3-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (25) 3-(5-{[3-(piperidin-1-yl)propyl]thioalkyl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (26) 3-(5-{[3-(pyrrolidone-1-yl)propyl]thioalkyl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (27) 3-(5-{[3-(azacycloheptane-1-yl)propyl]thioalkyl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (28) 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}piperidine-1-carboxylic acid phenyl ester (29) 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}piperidine-1-carboxylic acid ethyl ester (30) 3-{5-[(1-ethylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (31) 3-{5-[(1-butylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (32) 3-{5-[(1-pentylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (33) 3-(5-{[1-(cyclobutylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (34) 3-(5-{[1-(propane-2-yl)piperidin-4-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (35) 3-{5-[(1-butylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (36) 3-(5-{[1-(cyclopropylmethyl)piperidin-4-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (37) 3-{5-[(1-benzylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (38) 3-[5-({1-[(2-ethylphenyl)methyl]piperidin-4-yl}methoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (39) 3-{5-[(1-{[2-(trifluoromethyl)phenyl]methyl}piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (40) 3-[5-({1-[(3-fluorophenyl)methyl]piperidin-4-yl}methoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (41) 3-[5-({1-[(3-bromophenyl)methyl]piperidin-4-yl}methoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (42) 3-{5-[(1-acetylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (43) 3-{5-[(1-propionylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (44) 4-({[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}methyl)piperidine-1-carboxylic acid methyl ester (45) 4-({[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}methyl)piperidin-1-propane-2-yl ester) (46) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid methyl ester (47) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid ethyl ester (48) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid propyl ester (49) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-propane-2-yl ester (50) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid benzyl ester (51) 3-{5-[3-(azacycloheptane-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (52) 3-{5-[2-(azacycloheptane-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (53) 3-{5-[2-(4-methoxypiperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (54) 3-{5-[2-(3-methoxypiperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (55) 3-[5-(2-{7-azaspiro[4.5]decane-7-yl}ethoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (56) 3-[5-(2-{9-oxa-2-azaspiro[5.5]undecane-2-yl}ethoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (57) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid tert-butyl ester (58) 3-{5-[2-(piperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (59) 3-{5-[2-hydroxy-3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (60) 3-{5-[3-(4-hydroxypiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (61) 3-{5-[3-(3-hydroxypiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (62) 3-{5-[3-(morpholin-4-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (63) 3-{5-[3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (64) 3-[5-(3-{1,4-dioxa-8-azaspiro[4.5]decane-8-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (65) 1-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl)piperidin-4-one (66) 3-{5-[3-(3-fluoropiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (67) 3-{5-[3-(4-methylpiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (68) 3-{5-[3-(4-methoxypiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (69) 3-(5-{3-[(trans)3,4-dihydroxypiperidin-1-yl]propoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (70) 3-{5-[3-(4,4-difluoropiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (71) 3-{5-[3-(4-fluoro-4-methylpiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (72) 3-{5-[3-(4-acetylpiperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (73) 4-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl)piperazine-1-carboxylic acid methyl ester (74) 3-{5-[3-(piperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (75) 3-{5-[3-(4-benzylpiperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (76) 3-[5-(3-{3-azabicyclo[3.1.0]hexane-3-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (77) 3-[5-(3-{octahydrocyclopentanol[c]pyrrolo-2-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (78) 3-[5-(3-{7-azaspiro[4.5]decane-7-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (79) 3-[5-(3-{2-oxa-8-azaspiro[4.5]decane-8-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (80) 3-[5-(3-{9-oxa-2-azaspiro[5.5]undecane-2-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (81) 1-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl)pyridine-1-onium 4-methylbenzene-1-sulfonate (82) 3-{5-[(5-methyl-1,3-oxazol-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (83) 3-{5-[(1,3-thiazolyl-2-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (84) 3-{5-[3-(pyridin-3-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (85) 1-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl)piperidin-2-one (86) 3-{5-[2-methyl-3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (87) 3-{5-[2-(dimethylamino)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (88) 3-{5-[3-(dimethylamino)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (89) 3-{5-[4-(dimethylamino)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (90) 3-{5-[4-(piperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (91) 3-{5-[4-(azacycloheptane-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (92) 3-{5-[4-(pyrrolidone-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (93) 3-{5-[4-(3-hydroxypiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (94) 3-{5-[4-(morpholin-4-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (95) 3-{5-[4-(4-fluoropiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (96) 3-{5-[4-(4,4-dimethylpiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (97) 3-{5-[4-(3-hydroxy-3-methylpiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (98) 3-[5-(4-{7-azaspiro[4.5]decane-7-yl}butoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (99) 3-[5-(4-{9-oxa-2-azaspiro[5.5]undecane-2-yl}butoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (100) 4-(4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}butyl)piperazine-1-carboxylic acid methyl ester (101) 3-{5-[4-(4-acetylpiperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (102) 3-{5-[4-(piperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (103) 3-{5-[4-(4-benzylpiperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (104) 3-(5-{[5-(piperidin-1-yl)pentyl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (107) 3-(5-{[2-(pyridin-4-yl)ethyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (108) 3-(5-{[3-(piperidin-1-yl)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (109) 3-(5-{[(1-ethylpiperidin-4-yl)methyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (110) 3-(5-{methyl[3-(piperidin-1-yl)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (111) 3-(5-{[2-(dimethylamino)ethyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (112) 3-(5-{[3-(dimethylamino)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (113) 3-(5-{[4-(dimethylamino)butyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (114) 3-{5-[(1-ethylpiperidin-4-yl)amino]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (115) 3-{5-[(1-benzylpiperidin-4-yl)amino]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (116) 3-{5-[(1-ethylpiperidin-4-yl)(methyl)amino]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (117) 3-{5-[(1-benzylpiperidin-4-yl)(methyl)amino]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (118) 3-(5-{4-[2-(pyrrolidone-1-yl)ethyl]piperidin-1-yl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (119) 3-(5-{4-[2-(dimethylamino)ethyl]piperidin-1-yl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one.

[0016] [9] The compound or a pharmaceutically acceptable salt thereof, or a solvation thereof, wherein the compound is selected from the group consisting of the compounds listed in (7), (11), (12), (15) and (16) below: (7) 3-{5-[3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (11) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid phenyl ester (12) 3-{5-[2-(piperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (15) 3-{5-[(1-propylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (16) 3-(5-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one.

[0017]

[10] A pharmaceutical composition comprising, as an active ingredient, any one of [1] to [9], a compound or a pharmaceutically acceptable salt thereof, or a solvate thereof.

[0018]

[11] A treatment for myotonic dystrophy type 1, comprising any one of the compounds described in [1] to [9], or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.

[0019]

[12] Use of any compound or pharmaceutically acceptable salt thereof, or solvation thereof, in the manufacture of a therapeutic agent for myotonic dystrophy type 1.

[0020]

[13] The binding inhibitor inhibits the binding of CUG repeat RNA to MBNL protein and contains any one of the compounds described in [1] to [9] or a pharmaceutically acceptable salt thereof or a solvate thereof as the active ingredient.

[0021] Invention Effects According to the present invention, a compound having binding inhibitory activity that inhibits the binding of CUG repeat RNA to MBNL protein, or a pharmaceutically acceptable salt thereof, or a solvate thereof, may be provided. Detailed Implementation

[0022] The following describes in detail the methods for implementing the present invention. However, the present invention is not limited to the following embodiments.

[0023] In this specification, "alkyl" refers to a monovalent group obtained by removing one hydrogen atom from a self-saturated hydrocarbon. Alkyl groups can be straight-chain or branched. Alkyl groups can be C1-C6, C1-C4, or C1-C3. Additionally, in this specification, "C..." a ~C b "This refers to a to b carbon atoms. Specific examples of alkyl groups include straight-chain alkyl groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, and n-hexyl; and branched-chain alkyl groups such as isopropyl (1-methylethyl), sec-butyl, isobutyl (2-methylpropyl), tert-butyl, neopentyl, isopentyl, sec-pentyl, 3-pentyl, tert-pentyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1,1,2,2-tetramethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, and 2-ethylbutyl."

[0024] In this specification, "substituted alkyl" means a group in which one or more hydrogen atoms of an alkyl group are replaced by a substituent. Examples of substituents in substituted alkyl groups include, for example, hydroxyl, cyano, halogen, amino, monosubstituted amino, disubstituted amino, nitro, alkyl, cycloalkyl, alkoxy, aryloxy, heteroaryloxy, heterocyclic, aryl, acyl, oxo, etc. These substituents may be further replaced by other substituents, or they may bond together to form a ring.

[0025] In this specification, "dialkylamino" refers to a primary amino group in which two hydrogen atoms are independently replaced by an alkyl group. Dialkylamino groups can be C2 to C3. 12 Dialkylamino groups can be C2-C8 or C2-C6. Specific examples of dialkylamino groups include dimethylamino, methylethylamino, and diethylamino.

[0026] In this specification, "cycloalkyl" refers to a monovalent group obtained by removing one hydrogen atom from a cyclic saturated hydrocarbon. Cycloalkyl groups can be C3-C8, C3-C6, or C3-C5 cycloalkyl groups. Specific examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0027] In this specification, "substituted cycloalkyl" means a group in which one or more hydrogen atoms of a cycloalkyl group are replaced by a substituent. Examples of substituents in substituted cycloalkyl groups include the substituents described above.

[0028] In this specification, "alkylene" refers to a divalent group formed by removing two hydrogen atoms from a self-saturated hydrocarbon. Alkylenes can be straight-chain, branched, or cyclic, and can be either straight-chain or branched. Alkylenes can be C1-C6, C1-C5, or C1-C3. Specific examples of alkylenes include methylene, ethylene, propylene, isopropylene, butylene, pentylene, and hexylene.

[0029] In this specification, "hydroxyl-substituted alkylene" means an alkylene group, or a group in which one or more hydrogen atoms of an alkylene group are replaced by a hydroxyl group.

[0030] In this specification, "nitrogen-containing heterocyclic group" refers to a non-aromatic or aromatic cyclic monovalent group containing a nitrogen atom in its ring. The number of nitrogen atoms in the ring of a nitrogen-containing heterocyclic group can be, for example, 1 to 5, 1 to 3, or 1 to 2. Nitrogen-containing heterocyclic groups can be monocyclic, fused, or spirocyclic. They can have unsaturated bonds in the ring (unsaturated nitrogen-containing heterocyclic group) or not (saturated nitrogen-containing heterocyclic group). Specific examples of monocyclic nitrogen-containing heterocyclic groups include non-aromatic nitrogen-containing heterocyclic groups such as aziridine (e.g., 1-aziridine, 2-aziridine, 3-aziridine), piperidinyl (e.g., 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl), piperazine (e.g., 1-piperazine, 2-piperazine, 3-piperazine), pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl), and aziridine-heptyl (e.g., aziridine-1-yl, aziridine-2-yl, aziridine-3-yl); and pyridinyl (e.g., 2-pyridinyl, 3-pyridinyl, 4-pyridinyl), 1-pyridiniumyl, etc. Aromatic nitrogen-containing heterocyclic groups include pyrazinyl (e.g., 2-pyrazinyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl), triazinyl (1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl), pyrroloyl (e.g., 1-pyrroloyl, 2-pyrroloyl, 3-pyrroloyl), triazolyl (e.g., 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-4-yl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), and imidazoleyl (e.g., 1-imidazoleyl, 2-imidazoleyl, 4-imidazoleyl). Nitrogen-containing heterocyclic groups can be heterocyclic groups containing other heteroatoms besides a nitrogen atom. Specific examples include oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (e.g., 3-isooxazolyl, 4-isooxazolyl, 5-isooxazolyl), morpholinyl (e.g., 2-morpholinyl, 3-morpholinyl, 4-morpholinyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), and isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl), which are heterocyclic groups containing oxygen atoms.Specific examples of nitrogen-containing heterocyclic groups in fused rings include isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, 4-isoquinolinyl, 5-isoquinolinyl, 6-isoquinolinyl, 7-isoquinolinyl, 8-isoquinolinyl), quinazinyl (e.g., 2-quinazinyl), dihydroindolyl (e.g., 1-dihydroindolyl, 2-dihydroindolyl, 3-dihydroindolyl, 4-dihydroindolyl, 5-dihydroindolyl, 6-dihydroindolyl, 7-dihydroindolyl), and dihydroisoindolyl (e.g., 1-dihydroisoindolyl, 2-dihydroisoindolyl, 3-dihydroisoindolyl, 4-dihydroisoindolyl, 5-dihydroisoindolyl). Examples of nitrogen-containing heterocyclic groups that are spirocyclic include: 6-dihydroisoindolyl, 7-dihydroisoindolyl), tetrahydroquinolinyl (e.g., 1-tetrahydroquinolinyl, 2-tetrahydroquinolinyl, 3-tetrahydroquinolinyl, 4-tetrahydroquinolinyl, 5-tetrahydroquinolinyl, 6-tetrahydroquinolinyl, 7-tetrahydroquinolinyl, 8-tetrahydroquinolinyl), tetrahydroisoquinolinyl (e.g., 1-tetrahydroisoquinolinyl, 2-tetrahydroisoquinolinyl, 3-tetrahydroisoquinolinyl, 4-tetrahydroisoquinolinyl, 5-tetrahydroisoquinolinyl, 6-tetrahydroisoquinolinyl, 7-tetrahydroisoquinolinyl, 8-tetrahydroisoquinolinyl), azabicyclo[3.1.0]hexane-3-yl, octahydrocyclopentane[c]pyrrole-2-yl, etc. Specific examples of nitrogen-containing heterocyclic groups that are spirocyclic can be found in the groups shown below.

[0031] [Chemistry 2] In the formula, * represents the bonding position.

[0032] In this specification, "substituted nitrogen-containing heterocycle" means a group in which one or more elements (elements that do not form a ring) of a nitrogen-containing heterocycle are replaced by a substituent. The substituent can be bonded to either the nitrogen atom in the ring of the nitrogen-containing heterocycle or to a carbon atom. Examples of substituents in substituted heterocyclic groups include the aforementioned substituents.

[0033] In this specification, "aryl" refers to a monovalent group in a cyclic aromatic hydrocarbon. Aryl groups can be monocyclic or fused-ring. Specific examples of aryl groups include phenyl and naphthyl groups.

[0034] In this specification, "substituted aryl" means a group in which one or more elements (elements that do not form a ring) of an aryl group are replaced by a substituent. Examples of substituents in substituted aryl groups include the substituents described above.

[0035] In this specification, "alkoxy" refers to an oxygen group bonded to an alkyl group. Specific examples of alkoxy groups include methoxy, ethoxy, 1-propoxy, 2-propoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, 3-methylbutoxy, etc.

[0036] In this specification, "substituted alkoxy group" means a group in which one or more hydrogen atoms of an alkoxy group are replaced by a substituent. Examples of substituents in substituted alkoxy groups include the substituents described above.

[0037] In this specification, "aryloxy group" refers to an oxygen group bonded with an aryl group. Specific examples of aryloxy groups include phenoxy groups and naphthoxy groups.

[0038] In this specification, "substituted aryloxy group" means a group in which one or more elements (elements that do not form a ring) of an aryloxy group are replaced by a substituent. Examples of substituents in substituted aryloxy groups include the substituents described above.

[0039] In this specification, "heteroaryloxy" refers to an oxygen group bonded with a heteroaryl group. Specific examples of heteroaryloxy groups include furanyloxy, thiophenyloxy, pyrrolithyloxy, imidazolyloxy, pyrazolyloxy, thiazolyloxy, piperazineyloxy, etc.

[0040] In this specification, "substituted heteroaryloxy group" means a group in which one or more elements (elements that do not form a ring) of a heteroaryloxy group are replaced by a substituent. Examples of substituents in substituted heteroaryloxy groups include the substituents described above.

[0041] In this specification, "halogen" means a group consisting of halogen atoms (halogenated group). Examples of halogens include fluorine, chlorine, bromine, and iodine groups.

[0042] In this specification, "acyl" refers to a group comprising an atomic group formed by removing the OH group from the carboxyl group of a carboxylic acid. The acyl group can be C1 to C2. 10 Acyl groups can be C2-C8 acyl groups or C2-C3 acyl groups. Specific examples of acyl groups include methanoyl, ethanoyl, n-propionyl, and benzoyl.

[0043] The compounds of the present invention may be compounds represented by general formula (1) or pharmaceutically acceptable salts thereof, or solvates thereof.

[0044] [Chemistry 3] In general formula (1), X 1 X 2 and X 3 For any of the following combinations: (a) X 1 X 2 and X 3 -CH=; (b)X 1 For -N=, X 2 -CH=, X 3 -CH=; or (c)X 1 -CH=, X2 -CH=, X 3 For -N=, the preferred value is (a)X 1 X 2 and X 3 For -CH=. Additionally, in general formula (1), X is included. 1 X 2 and X 3 If the ring (a)X 1 X 2 and X 3 If -CH=, then it is a pyridine ring. If (b)X 1 For -N=, X 2 -CH=, X 3 If -CH=, then it is a pyrimidine ring, and (c)X 1 -CH=, X 2 -CH=, X 3 If -N = , then it is a pyridazine ring.

[0045] In general formula (1), A is -O-, -S-, -NR- or piperidinediyl, preferably -O-. In -NR-, R is a hydrogen atom or a C1 to C3 alkyl group.

[0046] When A is piperidinediyl, the nitrogen atom in the piperidine ring is preferably bonded to the carbon atom in the second ring from top to bottom in general formula (1). Specific examples of piperidinediyl include 1,4-piperidinediyl, 1,3-piperidinediyl, 1,2-piperidinediyl, etc.

[0047] In general formula (1), B is a single bond, a C1-C5 alkylene group, or a -Y bond. 1 -NY 2 -Y 3 - Preferably, it is a C1-C5 alkylene group, more preferably a C1-C3 alkylene group. -Y 1 -NY 2 -Y 3 -Medium, Y 1 and Y 3 Each independently represents a C1-C3 alkylene group, Y 2 It is a hydrogen atom or a C1-C3 alkyl group. B is -Y. 1 -NY 2 -Y 3 -At that time, Y 1 Bonded to A, Y 3 It bonds with C.

[0048] In general formula (1), C is a substituted or unsubstituted aryl group, or a substituted or unsubstituted nitrogen-containing heterocyclic group, preferably a substituted or unsubstituted nitrogen-containing heterocyclic group, more preferably a substituted or unsubstituted piperidinyl group, a substituted or unsubstituted piperazine group, or a substituted or unsubstituted pyrrolidinyl group. In addition, when C is a substituted or unsubstituted nitrogen-containing heterocyclic group, B can be bonded to the nitrogen atom in the ring of the nitrogen-containing heterocyclic ring, or it can be bonded to the carbon atom.

[0049] Examples of substituents in the above-mentioned C-substituted aryl or substituted nitrogen-containing heterocyclic groups include the above-mentioned substituents, preferably alkyl, cycloalkyl, cycloalkylalkyl, aryl, substituted aryl, benzyl, substituted benzyl, aryloxy, acyl, alkoxycarbonyl, aryloxycarbonyl, benzyloxycarbonyl, cycloalkylcarbonyl, or cycloalkoxycarbonyl.

[0050] Specific examples of alkyl, cycloalkyl, aryl, aryloxy, and acyl groups can be illustrated by the groups described above. Specific examples of cycloalkyl groups include cyclopropylmethyl and cyclobutylmethyl. Specific examples of substituted aryl groups include fluorophenyl. Specific examples of substituted benzyl groups include fluorobenzyl, bromobenzyl, trifluoromethylbenzyl, and ethylbenzyl. Specific examples of alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, and isobutoxycarbonyl. Specific examples of aryloxycarbonyl groups include phenoxycarbonyl. Specific examples of cycloalkylcarbonyl groups include cyclopropylcarbonyl. Specific examples of cycloalkoxycarbonyl groups include cyclopentoxycarbonyl.

[0051] The C mentioned above is preferably a nitrogen-containing heterocyclic group substituted with an alkyl, benzyl, or acyl group, or an unsubstituted nitrogen-containing heterocyclic group.

[0052] In general formula (1), at least one of B and C contains more than one nitrogen atom. The total number of nitrogen atoms contained in A, B and C can be 1 to 5, 1 to 3, or 1 to 2. The total number of nitrogen atoms contained in B and C can be 1 to 5, 1 to 3, or 1 to 2.

[0053] In general formula (1), when C is a substituted or unsubstituted nitrogen-containing heterocyclic group, B is preferably a single bond or a C1-C5 alkylene group; when C is a substituted or unsubstituted aryl group, B is preferably -Y. 1 -NY 2 -Y 3 -

[0054] In general formula (1), the following combination is further preferred: X 1 X 2 and X 3A is -CH=, B is -O-, B is a single bond or a C1-C5 alkylene group, and C is a nitrogen-containing heterocyclic group substituted with alkyl, benzyl or acyl, or an unsubstituted nitrogen-containing heterocyclic group, or a substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazine, or a substituted or unsubstituted pyrrolidinyl.

[0055] As specific examples of compounds represented by general formula (1), the compounds of (1) to (20) above (compounds of Examples 1 to 20) can be cited, and the compounds of (7), (11), (12), (15) and (16) above (compounds of Examples 7, 11, 12, 15 and 16) are preferred.

[0056] The compounds of the present invention can be manufactured using known compounds or intermediates that can be readily synthesized from known compounds, for example, according to the examples described later or known methods. In the manufacture of the compounds of the present invention, when the starting materials have substituents that affect the reaction, the starting materials are typically protected beforehand using a suitable protecting group by a known method before the reaction. The protecting group can be deprotected after the reaction using a known method.

[0057] The following explains the meanings of the terms used in this specification. Unless otherwise specified, each term shall have the same meaning when used alone or in combination with other terms.

[0058] The abbreviations used in this specification have the following meanings.

[0059] BSA: Bovine serum albumin DBU: 1,8-diazabicyclo[5.4.0]-7-undecene DMSO: Dimethyl sulfoxide CDI: 1,1'-carbonyldiimidazole KO t Bu: Potassium tert-Butoxide HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylureonium hexafluorophosphate HEPES: N-(2-hydroxyethyl)piperazine-N'-2-ethanesulfonic acid MeOH: Methanol MS: Mass spectrometry analysis LCMS: High Performance Liquid Chromatography-Mass Spectrometry ESI: Electrospray Ionization M: Molar concentration (mol / L).

[0060] The compounds of this invention can be used directly as pharmaceuticals or prepared by known methods into pharmaceutically acceptable salts, solvates, or solvates of salts. Examples of pharmaceutically acceptable salts include, for instance, salts of inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; salts of organic acids such as acetic acid, malic acid, lactic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, p-toluenesulfonic acid, benzenesulfonic acid, and methanesulfonic acid; or salts of alkali metals such as lithium, potassium, and sodium; salts of alkaline earth metals such as magnesium and calcium; and salts of organic bases such as ammonium salts. These salts can be formed by conventional methods.

[0061] For example, in the case where the compound of the present invention is a hydrochloride salt, it can be obtained by dissolving the free base of the compound of the present invention in an alcoholic solution of hydrogen chloride, an ethyl acetate solution of hydrogen chloride, a 1,4-dioxane solution of hydrogen chloride, a cyclopentylmethyl ether solution of hydrogen chloride, hydrochloric acid, or a diethyl ether solution of hydrogen chloride.

[0062] The compounds of this invention may absorb solvent molecules and become solvates upon exposure to the atmosphere or recrystallization, and such solvates are also included in the compounds of this invention. Such solvates include solvates of solvent molecules such as methanol, ethanol, isopropanol, butanol, dimethyl sulfoxide, and acetonitrile, as well as monohydrates and dihydrates.

[0063] A portion of the compounds of this invention has an asymmetric carbon, and all optical isomers and mixtures thereof are included in this invention. Stereoisomes can be prepared, for example, from racemic mixtures, by utilizing their basicity and optically active acids (tartaric acid, dibenzoyltartaric acid, mandelic acid, 10-camphorsulfonic acid, etc.) through known methods of optical resolution, or they can be prepared using pre-prepared optically active compounds as starting materials. Furthermore, they can also be prepared by optical resolution using chiral columns or by asymmetric synthesis.

[0064] The general formula (1) in this invention is not limited to a specific isomer, but includes all possible isomers and racemates. For example, the tautomers and stereoisomers shown below are also included in the compounds of this invention.

[0065] [Chemistry 4] The compounds of the present invention, as shown in the experimental examples described below, have binding inhibitory activity that inhibits the binding of CUG repeat RNA to MBNL protein.

[0066] Therefore, in one embodiment of the present invention, a binding inhibitor containing the compound of the present invention is provided to inhibit the binding of CUG repeat RNA to MBNL protein.

[0067] Furthermore, in one embodiment of the present invention, a binding inhibition method is provided, comprising administering the compound of the present invention to a target that requires it, thereby inhibiting the binding of CUG repeat RNA to MBNL protein.

[0068] Furthermore, in one embodiment of the present invention, the compound of the present invention is used in binding inhibition for inhibiting the binding of CUG repeat RNA to MBNL protein.

[0069] Furthermore, in one embodiment of the present invention, the use of the compound of the present invention in the manufacture of a binding inhibitor that inhibits the binding of CUG repeat RNA to MBNL protein is provided.

[0070] In one embodiment of the present invention, a therapeutic agent for myotonic dystrophy type 1 containing the compound of the present invention is provided.

[0071] Furthermore, in one embodiment of the present invention, a treatment method for myotonic dystrophy type 1 is provided, comprising administering the compound of the present invention to a subject in need of it.

[0072] Furthermore, in one embodiment of the present invention, the compound of the present invention is provided for use in the treatment of myotonic dystrophy type 1.

[0073] Furthermore, in one embodiment of the present invention, the use of the compound of the present invention in the manufacture of a therapeutic agent for myotonic dystrophy type 1 is provided.

[0074] Examples of diseases to which the compounds of the present invention can be applied include myotonic dystrophy type 1 and spinocerebellar ataxia type 8.

[0075] "Object" refers to a human or non-human animal suffering from or suspected of suffering from a disease or myotonic dystrophy type 1 associated with the binding of CUG repeat RNA to MBNL protein. In one embodiment of the invention, the object is a mammal. In another embodiment of the invention, the object is a human.

[0076] The compounds of the present invention can be directly or mixed with pharmacologically acceptable carriers to form, for example, pharmaceutical compositions containing 0.001% to 99.5%, preferably 0.1% to 90%, thereby being used as therapeutic agents for the aforementioned diseases in mammals such as humans, mice, rats, rabbits, dogs, cats, cattle, horses, pigs, and monkeys.

[0077] As a carrier, one or more pharmaceutically acceptable conventional solid, semi-solid, or liquid diluents, fillers, and other formulation adjuvants may be used. The pharmaceutical compositions of the present invention are ideally administered in unit form. The pharmaceutical compositions can be administered intramuscularly, orally, intravenously, topically (percutaneously, intraocularly, intrapleurally, etc.), or rectally. The pharmaceutical compositions of the present invention are administered in dosage forms suitable for these methods of administration.

[0078] Ideally, the dosage of the drug should be adjusted considering the patient's condition, such as age, weight, type and severity of disease, route of administration, type of compound of the present invention, whether it is a salt, and type of salt. Generally, for adults, the appropriate amount of active ingredient of the compound of the present invention or its pharmaceutically acceptable salt, when administered orally, is in the range of 0.01 mg to 5 g per adult per day, preferably in the range of 1 mg to 2000 mg per adult. Doses may be lower than this range, or conversely, there may be situations where higher doses are required. Typically, it can be administered once daily or in several divided doses, or in the case of intravenous administration, it can be administered rapidly or continuously over 24 hours.

[0079] One or more hydrogen, carbon, and / or other atoms in the compounds of the present invention may be substituted with isotopes of hydrogen, carbon, and / or other atoms. Examples of such isotopes include... 2 H, 3 H, 11 C 13 C 14 C 15 N、 18 O、 17 O、 31 P, 32 P, 35 S, 18 F, 123 I and 36 Cl represents hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine. This isotopically substituted compound is also useful as a pharmaceutical, containing all the radiolabeled components of the compounds of this invention.

[0080] The compounds disclosed herein can be manufactured, for example, by means of known compounds or intermediates that can be readily synthesized from known compounds, in accordance with the methods described herein or known methods.

[0081] If the solvents, reagents, and raw materials used in each step of the following manufacturing methods are commercially available, they can be used directly. Furthermore, the compounds obtained and the raw materials used in each step of the following manufacturing methods can form salts, or can be converted into other types of salts or free forms using known methods. When the compounds obtained and the raw materials used in each step of the following manufacturing methods are free forms, they can be converted into the target salt using known methods. Examples of such salts include those identical to the salts used in the compounds disclosed above.

[0082] In the preparation of the compounds disclosed herein, if the starting material has substituents that may affect the reaction, these substituents can be pre-treated with a protecting group using known methods. When the starting material is treated with a protecting group, the protecting group can be removed as needed after the reaction, thereby obtaining the target compound. Examples of such protecting groups include those shown in, for example, Wuts and Greene's "Greene's Protective Groups in Organic Synthesis," 4th edition; John Wiley & Sons Inc., 2006; or PJ Kocienski's "Protecting Groups," 3rd edition; Thieme, 2005. The protecting group can be appropriately selected based on the properties of the starting material and the reaction conditions.

[0083] The compounds obtained in each step of the following manufacturing method can be separated or purified by conventional methods such as solvent extraction, concentration, distillation, sublimation, recrystallization, recrystallization, and chromatography, or they can be used in the next step as a reaction mixture or crude purified product.

[0084] Unless otherwise specified, the reactions in each step of the following manufacturing method may be carried out by appropriately modifying or combining well-known methods, such as those described in R.C. Larock's "Comprehensive Organic Transformations: A Guide to Functional Group Preparations 2nd Edition" (John Wiley & Sons Inc., 1999); the Chemical Society of Japan's "Lectures on Experimental Chemistry" 4th edition (Maruzen, 1992); L. Kuerti and B. Czako's "Strategic Application of Named Reactions in Organic Synthesis" (translated by Kiyoshi Tomioka) (Chemical Dojin, 2006); and GS. Z. Weifel and MH. Nantz's "The Latest Organic Synthesis Methods: Design and Strategy" (translated by Kimijiro Hiyama) (Chemical Dojin, 2009), or the methods described in this specification. A more specific method for manufacturing the disclosed compound is described below.

[0085] Compound (1) can be manufactured by the following methods.

[0086] [Chemistry 5] X 1 X 2 X 3 A, B, and C have the same meaning as described above. E 1 This indicates a leaving group, and examples include halogens such as fluorine and chlorine; methanesulfonates, toluenesulfonates, trifluoromethanesulfonates, etc. E 2 This indicates a leaving group, such as chlorine or imidazole.

[0087] Path 1 Step 1 This step involves reacting a commercially available compound A-1, or one synthesized by known methods, with a hydroxylamine hydrochloride or hydroxylamine in solvents such as ethanol, methanol, water, tetrahydrofuran, or dimethyl sulfoxide, in the presence of a base such as potassium tert-butoxide, sodium tert-butoxide, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium bicarbonate, diisopropylethylamine, or triethylamine, at a temperature of 0°C to 100°C, preferably 10°C to 80°C, more preferably 20°C to 40°C, for 5 minutes to 48 hours, preferably 10 minutes to 24 hours, more preferably 30 minutes to 6 hours, thereby obtaining compound A-2. Compound A-2 can sometimes be obtained as a salt of an inorganic acid.

[0088] Step 2 The reaction proceeds as follows: Compound A-2 is reacted with commercially available or synthesized compound A-3 by known methods in solvents such as acetonitrile, tetrahydrofuran, or dioxane, in the presence of bases such as diisopropylethylamine, triethylamine, or DBU, at a temperature of 0°C to 50°C, preferably 10°C to 40°C, and more preferably 20°C to 30°C, for 5 minutes to 24 hours, preferably 10 minutes to 12 hours, and more preferably 30 minutes to 6 hours, thereby obtaining compound A-4.

[0089] Step 3 This reaction involves reacting compound A-4 with commercially available or synthesized compound A-5 by known methods in solvents such as N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and tetrahydrofuran, in the presence of bases such as potassium tert-butoxide, sodium tert-butoxide, potassium carbonate, sodium hydride, diisopropylethylamine, triethylamine, and DBU, at 0°C to 120°C, preferably 30°C to 80°C, and more preferably 50°C to 70°C, for 5 minutes to 48 hours, preferably 10 minutes to 12 hours, and more preferably 30 minutes to 4 hours, to obtain compound (1).

[0090] In addition, compound (1) can also be produced by the following steps: after introducing a substituent equivalent to ABC, the cyano (-CN) is converted to 4,5-dihydro-1,2,4-oxadiazol-5-one.

[0091] [Chemistry 6] X 1 X 2 X 3 A, B, C, E 1 E 2 Same meaning as mentioned above.

[0092] Path 2 Step 1 The steps are as follows: Compound A-1, commercially available or synthesized by known methods, is reacted with compound A-5, commercially available or synthesized by known methods, in solvents such as N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and tetrahydrofuran, in the presence of bases such as potassium tert-butoxide, sodium tert-butoxide, sodium hydride, potassium carbonate, diisopropylethylamine, triethylamine, and DBU, at 0°C to 120°C, preferably 10°C to 100°C, more preferably 20°C to 30°C, for 5 minutes to 48 hours, preferably 10 minutes to 12 hours, more preferably 30 minutes to 6 hours, to obtain compound B-1.

[0093] Step 2 This reaction is the step from compound B-1 to compound B-2, and can be produced by the same method as step 1 of the above-described pathway 1.

[0094] Step 3 This reaction is the step of obtaining compound (1) from compound B-2, which can be produced by the same method as step 2 of the above-mentioned path 1.

[0095] Compound B-1 can also be produced by the following methods.

[0096] [Chemistry 7] X 1 X 2 X 3 A, B, C, E 1 Same meaning as mentioned above. E 3 Examples of leaving groups include halogens such as chlorine, bromine, and iodine; and esters such as methanesulfonates, toluenesulfonates, and trifluoromethanesulfonates.

[0097] Path 3 Step 1 This step involves reacting a commercially available compound A-1, or a compound synthesized by a known method, with a commercially available compound C-1, or a compound synthesized by a known method, in solvents such as N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, or tetrahydrofuran, in the presence of a base such as potassium tert-butoxide, sodium tert-butoxide, sodium hydride, potassium carbonate, diisopropylethylamine, triethylamine, or DBU, at a temperature of 0°C to 120°C, preferably 10°C to 100°C, more preferably 20°C to 30°C, for 5 minutes to 48 hours, preferably 10 minutes to 12 hours, more preferably 30 minutes to 6 hours, to obtain compound C-2. Additionally, the hydroxyl group of compound C-1 is sometimes protected by a known protecting group; this protection can be removed after the addition reaction using a known method.

[0098] Step 2 This step, which yields compound C-3 from compound C-2, can be carried out using a known method. For example, compound C-2 can be reacted with a sulfonating agent such as toluenesulfonyl chloride, methanesulfonyl chloride, or p-toluenesulfonic anhydride in a solvent such as dichloromethane or tetrahydrofuran, in the presence of a base such as pyridine, diisopropylethylamine, triethylamine, or DBU, at a temperature of 0°C to 50°C, preferably 10 to 30°C, for 1 hour to 48 hours, preferably 2 hours to 6 hours, to obtain compound C-3.

[0099] Step 3 This step involves introducing C into compound C-3 to obtain compound B-1, and can be carried out according to known methods. For example, compound C-2 can be reacted with a secondary amine such as piperidine or pyrrolidone in solvents such as N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, or tetrahydrofuran, in the presence of a base such as sodium hydride, potassium carbonate, diisopropylethylamine, triethylamine, or DBU, at 40°C to 120°C, preferably 80°C to 100°C, for 1 hour to 48 hours, preferably 3 hours to 12 hours, thereby obtaining compound B-1.

[0100] In addition, compound (1) can also be produced by the following method: that is, by a chemical reaction following the addition of B with a hydroxyl group.

[0101] [Chemistry 8] X 1 X 2 X 3 A, B, C, E 1 E 3 Same meaning as mentioned above.

[0102] Path 4 Step 1 This step involves reacting compound A-4 with commercially available or synthesized compound C-1 by known methods in solvents such as N-methyl-2-pyrrolidone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, and tetrahydrofuran, in the presence of bases such as potassium tert-butoxide, sodium tert-butoxide, sodium hydride, potassium carbonate, diisopropylethylamine, triethylamine, and DBU, at a temperature of 0°C to 120°C, preferably 20°C to 80°C, more preferably 50°C to 70°C, for 5 minutes to 48 hours, preferably 10 minutes to 12 hours, more preferably 30 minutes to 6 hours, to obtain compound D-1. Additionally, the hydroxyl group of compound C-1 is sometimes protected by a known protecting group, which can be removed by known methods after the addition reaction.

[0103] Step 2 This step involves converting the hydroxyl group of compound D-1 and introducing a leaving group to obtain compound D-2. The reaction is carried out under the same conditions as the synthesis of compound (C-3) above, thereby obtaining D-2.

[0104] Step 3 This step is to convert the leaving group of compound D-2 and introduce C to obtain compound (1), which can be manufactured by the same method as step 3 of the above path 3. Example

[0105] The following examples and test cases further illustrate the present invention in detail, but they are not intended to limit the invention to these examples.

[0106] MS was determined by LC-MS. ESI was used as the ionization method. The observed mass spectrometry values ​​are expressed as m / z.

[0107] The determination conditions for LCMS are as follows.

[0108] Analysis equipment: ACQUITY UPLC MS / PDA system (made by Waters Corporation) Mass spectrometer: ACQUITY QDa detector or Waters 3100 MS detector Photodiode array detector: ACQUITY PDA detector (UV detection wavelength: 210~400nm) Column: Acquity BEH C18, 1.7μm, 2.1×50mm Flow rate: 0.5 mL / min Column temperature: 40℃ Solvent; Solution A: 0.1% formic acid / H2O (v / v; same applies below) Solution B: 0.1% formic acid / acetonitrile Nuclear magnetic resonance (NMR) spectroscopy was performed using a JNM-ECS400 NMR apparatus (manufactured by JEOL RESONANCE Co., Ltd.) or a JNM-ECZL400S NMR apparatus (manufactured by Nippon Electron Co., Ltd.). Observed peaks were expressed as chemical shift values ​​δ (ppm) (s = singlet, d = doublet, t = triplet, q = quartet, br = broad singlet, m = multiplet, dd = double doublet, ddd = double doublet, dt = double triplet).

[0109] Microwave experiments used an initiator (Biotage system) or an initiator+ (Biotage system).

[0110] The compound names in this specification are made using naming software in accordance with IUPAC rules, ACD / NAME (registered trademark, Advanced Chemistry Development Inc.), or ChemBioDraw (version 19.1, Cambridge Soft), or in accordance with IUPAC nomenclature.

[0111] Example 1 3-{5-[(1-ethylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-oxazolium hydrochloride [Step 1] Preparation of 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxynitrile In a mixture of (1-ethylpiperidin-4-yl)methanol (528 mg) and N,N-dimethylformamide (2.46 mL), sodium hydride (60%, dispersed in liquid paraffin, 147 mg) was added, and the mixture was stirred at room temperature for 15 minutes. Then, 5-fluoropyridine-2-carboxynitrile (300 mg) was added, and the mixture was stirred overnight. Water was added to the reaction mixture under ice-cooling, and the mixture was diluted with ethyl acetate. After washing with water and saturated brine, the solution was dried over anhydrous sodium sulfate. The solvent was removed by vacuum distillation, and the residue was purified by silica gel chromatography to give the title compound (500 mg).

[0112] MS (m / z): 246.3[M+H] + [Step 2] Preparation of 5-[(1-ethylpiperidin-4-yl)methoxy]-N'-hydroxypyridine-2-carboximide amide In a mixture of hydroxylamine hydrochloride (425 mg) and dimethyl sulfoxide (2.04 mL), KO was added sequentially at room temperature. t Bu (686 mg) was stirred for 10 minutes. 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxynitrile (500 mg) was added and stirred overnight. Water was added to the reaction solution, the precipitate was filtered off, and dried to give the title compound (396 mg).

[0113] MS (m / z): 279.3[M+H] + [Step 3] Preparation of 3-{5-[(1-ethylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride In a mixture of 5-[(1-ethylpiperidin-4-yl)methoxy]-N'-hydroxypyridine-2-carboximide amide (396 mg), tetrahydrofuran (4.74 mL), and DBU (0.255 mL), CDI (277 mg) was added, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, and hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel chromatography to give the title compound (98 mg).

[0114] MS (m / z): 305.0[M+H] + 1H-NMR (400MHz, DMSO-d6) δ: 8.39 (d, 1H), 7.89 (d, 1H), 7.57 (dd, 1H), 4.05 (d, 2H), 3.50-3.12 (m , 2H), 2.92-2.82 (m, 2H), 2.74-2.60 (m, 2H), 2.10-1.88 (m, 3H), 1.60-1.42 (m, 2H), 1.17 (t, 3H).

[0115] Example 2 3-(5-{[(3R)-1-ethylpiperidin-3-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4- Oxadiazole-5-one hydrochloride [Step 1] Preparation of (3R)-3-{[(6-cyanopyridin-3-yl)oxy]methyl}piperidine-1-carboxylic acid tert-butyl ester In a mixture of (3R)-3-(hydroxymethyl)piperidin-1-carboxylic acid tert-butyl ester (410 mg) and N,N-dimethylformamide (1.27 mL), sodium hydride (60%, dispersed in liquid paraffin, 76 mg) was added, and the mixture was stirred at room temperature for 15 minutes. Then, 5-fluoropyridine-2-carboxynitrile (155 mg) was added, and the mixture was stirred overnight. Water was added to the reaction mixture under ice-cooling, and the mixture was diluted with ethyl acetate. After washing with water and saturated brine, the solution was dried over anhydrous sodium sulfate. The solvent was removed by vacuum distillation, and the residue was purified by silica gel chromatography to give the title compound (310 mg).

[0116] MS (m / z): 318.1[M+H] + [Step 2] Preparation of 5-{[(3R)-piperidin-3-yl]methoxy}pyridine-2-carboxynitrile hydrochloride In (3R)-3-{[(6-cyanopyridin-3-yl)oxy]methyl}piperidine-1-carboxylic acid tert-butyl ester (310 mg), a 4 M dioxane solution (3.0 mL) was added at room temperature and stirred for 1 hour. The solvent was then removed by vacuum distillation to give the title compound (310 mg).

[0117] MS (m / z): 218.0[M+H] + .

[0118] [Step 3] Preparation of 5-{[(3R)-1-ethylpiperidin-3-yl]methoxy}pyridine-2-carboxynitrile In a mixture of 5-{[(3R)-piperidin-3-yl]methoxy}pyridine-2-carboxynitrile hydrochloride (310 mg), N,N-dimethylformamide (3 mL), and diisopropylethylamine (0.92 mL), iodoethane (217 mg) was added, and the mixture was heated and stirred overnight at 70 °C. The reaction solution was purified by silica gel column chromatography to give the title compound (66 mg).

[0119] MS (m / z): 246.1[M+H] + .

[0120] [Step 4] Preparation of 3-(5-{[(3R)-1-ethylpiperidin-3-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (48 mg) was obtained by replacing 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile with 5-{[(3R)-1-ethylpiperidin-3-yl]methoxy}pyridine-2-carboxylonitrile (66 mg).

[0121] MS (m / z): 305.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.45 (d, 1H), 7.79 (d, 1H), 7.46 (dd, 1H), 4.06 (d, 2H), 3.93 (t , 2H), 2.85 (d, 2H), 3.55-3.20 (m, 3H), 2.22-2.08 (m, 1H), 1.85-1.60 (m, 3H), 1.15 (t, 3H) Elemental analysis values ​​(in C) 15 H 20 (N4O3·HCl) Calculated values ​​(%): C: 52.86, H: 6.21, N: 16.44 Measured values ​​(%) C: 53.30, H: 6.61, N: 16.43.

[0122] Example 3 3-(5-{[(3S)-1-ethylpiperidin-3-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4- Oxadiazole-5-one hydrochloride By using (3S)-3-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester (410 mg) instead of (3R)-3-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester in step 1 of Example 2, the title compound (24 mg) was obtained.

[0123] MS (m / z): 305.1[M+H] + .

[0124] Example 4 3-{5-[(1-benzylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto Hydrochloride [Step 1] Preparation of 5-[(1-benzylpiperidin-4-yl)oxy]pyridine-2-carboxynitrile By using 1-benzylpiperidin-4-ol (470 mg) instead of (1-ethylpiperidin-4-yl)methanol according to step 1 of Example 1, the title compound (400 mg) was obtained.

[0125] MS (m / z): 294.1[M+H] + .

[0126] [Step 2] Preparation of 3-{5-[(1-benzylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (390 mg) was obtained by replacing 5-[(1-benzylpiperidin-4-yl)oxy]pyridine-2-carboxylonitrile with the 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile obtained in step 1 of Example 4.

[0127] MS (m / z): 353.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 10.75 (br, 1H), 8.48 (d, 1H), 7.95 (d, 1H), 7.70 (dd, 1H), 7.66-7.58 (m, 2H), 7. 50-7.44 (m, 3H), 5.10-4.70 (m, 1H), 4.34 (s, 2H), 3.30-3.00 (m, 4H), 2.30-2.18 (m, 2H), 2.14-1.98 (m, 2H).

[0128] Example 5 3-(5-{2-[benzyl(methyl)amino]ethoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazine 5-Azolium [Step 1] Preparation of 5-{2-[benzyl(methyl)amino]ethoxy}pyridine-2-carboxynitrile By following the method in step 1 of Example 1, 2-[benzyl(methyl)amino]ethane-1-ol (406 mg) was used instead of (1-ethylpiperidin-4-yl)methanol to obtain the title compound (430 mg).

[0129] MS (m / z): 268.2[M+H] + .

[0130] [Step 2] 3-(5-{2-[benzyl(methyl)amino]ethoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one By following steps 2 and 3 of Example 1, the title compound (300 mg) was obtained by using 5-{2-[benzyl(methyl)amino]ethoxy}pyridine-2-carboxylonitrile (430 mg) instead of 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile].

[0131] MS (m / z): 327.0[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.43 (d, 1H), 7.92 (d, 1H), 7.61 (dd, 1H), 7.33-7.22 (m, 5H), 4.29 (t, 2H), 3.60 (s, 2H), 2.80 (t, 2H), 2.26 (s, 3H) Elemental analysis values ​​(in C) 17 H 18 (Calculated as N4O3・0.1H2O) Calculated values ​​(%): C: 62.22, H: 5.59, N: 17.07 Measured values ​​(%) C: 62.06, H: 5.59, N: 16.96.

[0132] Example 6 3-{5-[2-(4-acetylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4- Oxadiazole-5-one hydrochloride [Step 1] Preparation of 4-{2-[(6-cyanopyridin-3-yl)oxy]ethyl}piperazine-1-carboxylic acid tert-butyl ester In a mixture of 1.42 g of tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate and 4.10 mL of N,N-dimethylformamide, sodium hydride (60%, dispersed in liquid paraffin, 246 mg) was added, and the mixture was stirred for 15 minutes at room temperature. Then, 5-fluoropyridine-2-carboxynitrile (500 mg) was added, and the mixture was stirred overnight. Water was added to the reaction mixture under ice-cooling, and the mixture was purified by silica gel column chromatography to give the title compound (1.97 g).

[0133] MS (m / z): 333.3[M+H] + .

[0134] [Step 2] Preparation of 5-[2-(piperazin-1-yl)ethoxy]pyridine-2-carboxynitrile dihydrochloride In a mixture of 1.97 g of 4-{2-[(6-cyanopyridin-3-yl)oxy]ethyl}piperazine-1-carboxylic acid tert-butyl ester and 2.85 mL of methanol, 4 M dioxane hydrochloride solution (4.44 mL) was added, and the mixture was stirred at room temperature for 30 minutes. Then, 2.85 mL of methanol and 4 M dioxane hydrochloride solution (4.44 mL) were added, and the mixture was stirred overnight. The precipitate was filtered off, dried, and the title compound (0.97 g) was obtained.

[0135] MS (m / z): 233.2[M+H] + .

[0136] [Step 3] Preparation of 5-[2-(4-acetylpiperazin-1-yl)ethoxy]pyridine-2-carboxynitrile In a mixture of 5-[2-(piperazin-1-yl)ethoxy]pyridine-2-carboxynitrile dihydrochloride (300 mg), dichloromethane (3.28 mL), and diisopropylethylamine (0.85 mL), acetyl chloride (0.084 mL) was added sequentially under ice-cooling, and the mixture was stirred at room temperature for 5 hours. A few drops of saturated sodium bicarbonate solution were added to the reaction mixture, and the solution was concentrated under reduced pressure. Purification was performed by silica gel column chromatography to obtain the title compound (242 mg).

[0137] MS (m / z): 275.2[M+H] + .

[0138] [Step 4] Preparation of 3-{5-[2-(4-acetylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (207 mg) was obtained by using 5-[2-(4-acetylpiperazin-1-yl)ethoxy]pyridine-2-carboxylonitrile (242 mg) instead of 5-[1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile (242 mg) obtained in step 3 of Example 6.

[0139] MS (m / z): 334.0[M+H] + 1 H-NMR (400MHz, D2O) δ: 8.24 (d, 1H), 7.72 (d, 1H), 7.42 (dd, 1H), 4.39 (t, 2H), 3.80-3.67 (m, 4H), 3.42 (t, 2H), 3.25-3.11 (m, 4H), 2.09 (s, 3H).

[0140] Example 7 3-{5-[3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole-5- Ketone hydrochloride [Step 1] Preparation of 5-[3-(piperidin-1-yl)propoxy]pyridine-2-carboxynitrile In a mixture of 3-(piperidin-1-yl)propane-1-ol (387 mg) and N,N-dimethylformamide (3.0 mL), sodium hydride (60%, dispersed in liquid paraffin, 108 mg) was added, and the mixture was stirred at room temperature for 15 minutes. Then, 5-fluoropyridine-2-carboxynitrile (220 mg) was added, and the mixture was stirred overnight at room temperature. Water was added to the reaction mixture under ice-cooling, and the mixture was diluted with ethyl acetate. After washing with water and saturated brine, the solution was dried over anhydrous sodium sulfate. The solvent was removed by vacuum distillation, and the residue was purified by silica gel column chromatography to give the title compound (336 mg).

[0141] MS (m / z): 246.2[M+H] + .

[0142] [Step 2] Preparation of N'-hydroxy-5-[3-(piperidin-1-yl)propoxy]pyridine-2-carboximide amide In a mixture of hydroxylamine hydrochloride (530 mg) and ethanol (3.0 mL), 3.42 mL of 2 M sodium hydroxide aqueous solution was added, and the mixture was stirred for 10 minutes at room temperature. 5-[3-(piperidin-1-yl)propoxy]pyridine-2-carboxynitrile (336 mg) was added to the reaction mixture, and the mixture was stirred for 4 hours. Water was added to the reaction mixture, the precipitate was filtered off, and dried to give the title compound (236 mg).

[0143] MS (m / z): 279.3[M+H] + .

[0144] [Step 3] Preparation of 3-{5-[3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride In a mixture of N'-hydroxy-5-[3-(piperidin-1-yl)propoxy]pyridine-2-carboximide amide (236 mg), tetrahydrofuran (5.0 mL), and DBU (0.19 mL), CDI (206 mg) was added at room temperature and the mixture was stirred for 5 hours. Water was added to the reaction solution, and hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (190 mg).

[0145] MS (m / z): 305.2[M+H] + 1H-NMR (400MHz, D2O) δ: 8.23 ​​(d, 1H), 7.62 (d, 1H), 7.41 (dd, 1H), 4.24 (t, 2H), 3.69 (br, 2H), 3.43-3.3 9 (m, 2H), 3.08 (ddd, 2H), 2.39-2.32 (m, 2H), 2.08-2.05 (m, 2H), 1.95-1.79 (m, 3H), 1.65-1.55 (m, 1H) Elemental analysis values ​​(in C) 15 H 20 (N4O3·HCl) Calculated values ​​(%): C: 52.86, H: 6.21, N: 16.44 Measured values ​​(%) C: 52.71, H: 6.31, N: 16.52.

[0146] Example 8 3-{5-[3-(pyrrolidone-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto Hydrochloride [Step 1] Preparation of 5-[3-(pyrrolidone-1-yl)propoxy]pyridine-2-carboxynitrile By following the method in step 1 of Example 1, 3-(pyrrolidone-1-yl)propane-1-ol (349 mg) was used instead of (1-ethylpiperidin-4-yl)methanol to obtain the title compound (296 mg).

[0147] MS (m / z): 232.2[M+H] + .

[0148] [Step 2] Preparation of 3-{5-[3-(pyrrolidone-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (250 mg) was obtained by replacing 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile with 5-[3-(pyrrolidine-1-yl)propoxy]pyridine-2-carboxylonitrile (296 mg).

[0149] MS (m / z): 291.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.28 (br, 1H), 7.74 (d, 1H), 7.36 (d, 1H), 4.16 (t, 2H), 3.30-3.15 (m, 6H), 2.15-2.06 (m, 2H), 1.94-1.87 (m, 4H).

[0150] Example 9 3-{5-[2-(pyrrolidone-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto Hydrochloride [Step 1] Preparation of 5-[2-(pyrrolidone-1-yl)ethoxy]pyridine-2-carboxynitrile By following the method in step 1 of Example 1, 2-(pyrrolidine-1-yl)ethane-1-ol (325 mg) was used instead of (1-ethylpiperidin-4-yl)methanol to obtain the title compound (350 mg).

[0151] MS (m / z): 218.0[M+H] + [Step 2] Preparation of 3-{5-[2-(pyrrolidone-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (330 mg) was obtained by replacing 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile with 5-[2-(pyrrolidine-1-yl)ethoxy]pyridine-2-carboxylonitrile (350 mg).

[0152] MS (m / z): 277.0[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.37 (d, 1H), 7.80 (d, 1H), 7.43 (dd, 1H), 4.34 (t, 2H), 3.35 (t, 2H), 3.18-3.12 (m, 4H), 1.92-1.86 (m, 4H).

[0153] Example 10 3-{5-[2-(4-benzylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa diazol-5-one [Step 1] Preparation of 5-[2-(4-benzylpiperazin-1-yl)ethoxy]pyridine-2-carboxynitrile In a mixture of 5-[2-(piperazin-1-yl)ethoxy]pyridine-2-carboxynitrile dihydrochloride (228 mg), N,N-dimethylformamide (3 mL), and diisopropylethylamine (0.65 mL) obtained in step 2 of Example 6, bromomethylbenzene (0.11 mL) was added at room temperature and the mixture was stirred overnight. A saturated sodium bicarbonate solution was added to the reaction mixture, and purification was performed by silica gel column chromatography to obtain the title compound (235 mg).

[0154] MS (m / z): 323.3[M+H] + .

[0155] [Step 2] Preparation of 3-{5-[2-(4-benzylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one By following steps 2 and 3 of Example 1, the title compound (105 mg) was obtained by using 5-[2-(4-benzylpiperazin-1-yl)ethoxy]pyridine-2-carboxylonitrile (235 mg) instead of 5-[1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile (235 mg) obtained in step 1 of Example 10.

[0156] MS (m / z): 382.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.42 (d, 1H), 7.91 (d, 1H), 7.61 (dd, 1H), 7.40-7.20 (m , 5H), 4.25 (t, 2H), 3.50 (s, 2H), 3.40-3.20 (m, 4H), 2.76 (t, 2H), 2.45-2.30 (m, 4H) Elemental analysis values ​​(in C) 20 H 23 (Calculated as N5O3・0.1H2O) Calculated values ​​(%): C: 62.68, H: 6.10, N: 18.28 Measured values ​​(%) C: 62.42, H: 6.09, N: 18.26.

[0157] Example 11 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} Ethyl)piperazine-1-carboxylic acid phenyl ester hydrochloride [Step 1] Preparation of 4-{2-[(6-cyanopyridin-3-yl)oxy]ethyl}piperazine-1-carboxylic acid phenyl ester In a mixture of 5-[2-(piperazin-1-yl)ethoxy]pyridine-2-carboxynitrile dihydrochloride (220 mg), dichloromethane (2.40 mL), and diisopropylethylamine (0.62 mL) obtained in step 2 of Example 6, phenyl chloroformate (0.11 mL) was added under ice-cooling, and the mixture was stirred at room temperature. A few drops of saturated sodium bicarbonate solution were added to the reaction mixture, and the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give the title compound (254 mg).

[0158] MS (m / z): 353.2[M+H] + .

[0159] [Step 2] Preparation of 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid phenyl ester hydrochloride] By following steps 2 and 3 of Example 1, the title compound (208 mg) was obtained by using 4-{2-[(6-cyanopyridin-3-yl)oxy]ethyl}piperazine-1-carboxylic acid phenyl ester (254 mg) obtained in step 1 of Example 11 instead of 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonate.

[0160] MS (m / z): 412.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 11.2 (br, 1H), 8.52 (d, 1H), 8.01 (d, 1H), 7.70 (dd, 1H), 7.43-7.38 (m, 2H), 7.2 7-7.20 (m, 1H), 7.18-7.12 (m, 2H), 4.63 (br, 2H), 4.40-4.00 (m, 2H), 3.75-3.55 (m, 4H), 3.35-3.20 (m, 4H) Elemental analysis values ​​(in C) 20 H 21 (N5O5・HCl) Calculated values ​​(%): C: 53.63, H: 4.95, N: 15.64 Measured values ​​(%) C: 53.19, H: 5.03, N: 15.46.

[0161] Example 12 3-{5-[2-(piperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto Hydrochloride [Step 1] Preparation of 5-[2-(piperidin-1-yl)ethoxy]pyridine-2-carboxynitrile By following the method in step 1 of Example 1, 2-(piperidin-1-yl)ethane-1-ol (794 mg) was used instead of (1-ethylpiperidin-4-yl)methanol to obtain the title compound (758 mg).

[0162] MS (m / z): 232.2[M+H] + [Step 2] Preparation of 3-{5-[2-(piperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (480 mg) was obtained by using 5-[2-(piperidin-1-yl)ethoxy]pyridine-2-carboxylonitrile (758 mg) instead of 5-[1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile (758 mg).

[0163] MS (m / z): 291.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.40 (d, 1H), 7.88 (d, 1H), 7.56 (dd, 1H), 4.29 (t , 2H), 2.91 (t, 2H), 2.70-2.64 (m, 4H), 1.61-4.54 (m, 4H), 1.46-1.38 (m, 2H).

[0164] Example 13 3-{5-[2-(4-phenoxypiperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4- Oxadiazole-5-one hydrochloride [Step 1] Preparation of 5-[2-(4-phenoxypiperidin-1-yl)ethoxy]pyridine-2-carboxynitrile By following the method in step 1 of Example 1, 2-(4-phenoxypiperidin-1-yl)ethane-1-ol (213 mg) was used instead of (1-ethylpiperidin-4-yl)methanol to obtain the title compound (192 mg).

[0165] MS (m / z): 324.2[M+H] + .

[0166] [Step 2] Preparation of 3-{5-[2-(4-phenoxypiperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (39 mg) was obtained by using 5-[2-(4-phenoxypiperidin-1-yl)ethoxy]pyridine-2-carboxylonitrile (192 mg) instead of 5-[1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile (192 mg) obtained in step 1 of Example 13.

[0167] MS (m / z): 383.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.44 (d, 1H), 7.92 (d, 1H), 7.63 (dd, 1H), 7.30-7.20 (m, 2H), 6.98-6.88 (m, 3H), 4 .43-4.33 (m, 1H), 4.29 (t, 2H), 2.90-2.80 (m, 4H), 2.48-2.38 (m, 2H), 2.00-1.90 (m, 2H), 1.70-1.60 (m, 2H).

[0168] Example 14 3-{5-[(1-cyclopropanecarbonylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2, 4-Oxadiazol-5-one [Step 1] Preparation of 4-{[(6-cyanopyridin-3-yl)oxy]methyl}piperidine-1-carboxylic acid tert-butyl ester In a mixture of tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate (7.94 g) and N,N-dimethylformamide (35 mL), sodium hydride (60%, dispersed in liquid paraffin, 1.47 g) was added, and the mixture was stirred at room temperature for 15 minutes. 5-Fluoropyridine-2-carboxynitrile (3.0 g) was added to the reaction mixture, and the mixture was stirred for 2 hours. Water was added to the reaction mixture under ice cooling, and the mixture was diluted with ethyl acetate. After washing with water and saturated brine, the mixture was dried over anhydrous sodium sulfate. The solvent was removed by vacuum distillation to give the title compound (7.8 g).

[0169] MS (m / z): 262.2 [M- t Bu+H] + .

[0170] [Step 2] Preparation of 4-[({6-[N'-hydroxymethylamidinyl]pyridin-3-yl}oxy)methyl]piperidine-1-carboxylic acid tert-butyl ester] In a mixture of hydroxylamine hydrochloride (8.5 g) and dimethyl sulfoxide (49 mL), KO was added under ice cooling. t Bu (14g) was stirred for 15 minutes. 4-{[(6-cyanopyridin-3-yl)oxy]methyl}piperidine-1-carboxylic acid tert-butyl ester (7.8g) was added to the reaction solution and stirred overnight. Water was added to the reaction solution, the precipitate was filtered off, and dried to obtain the title compound (7.72g).

[0171] MS (m / z): 351.3[M+H] + .

[0172] [Step 3] Preparation of tert-butyl piperidine-1-carboxylate {[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}methyl)piperidine-1-carboxylate In a mixture of 7.72 g of 4-[({6-[N'-hydroxymethylammonium]pyridin-3-yl]oxy)methyl]piperidin-1-carboxylic acid tert-butyl ester, tetrahydrofuran (44 mL), and DBU (3.95 mL), CDI (5.36 g) was added, and the mixture was stirred at room temperature for 2 hours. Water was added to the reaction solution, and 2 M hydrochloric acid was added dropwise to adjust the pH to 5. After 1 hour, the precipitate was filtered off, dried, and the title compound (7.5 g) was obtained.

[0173] MS (m / z): 375.2 [MH] - .

[0174] [Step 4] Preparation of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride In a mixture of 7.5 g of tert-butyl piperidine-1-carboxylate and 30 mL of tetrahydrofuran, 24.9 mL of 4 M dioxane hydrochloride solution was added at room temperature and stirred overnight. The solvent was removed by vacuum distillation, and the precipitate was filtered through diethyl ether and dried to give the title compound (7.24 g).

[0175] MS (m / z): 277.2[M+H] + .

[0176] [Step 5] Preparation of 3-{5-[(1-cyclopropanecarbonylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (150 mg), cyclopropanecarboxylic acid (53.7 mg), diisopropylethylamine (0.4 mL), and N,N-dimethylformamide (1 mL), HATU (219 mg) was added at room temperature and stirred overnight. The reaction mixture was purified by silica gel column chromatography to give the title compound (110 mg).

[0177] MS (m / z): 345.1[M+H] + .

[0178] Example 15 3-{5-[(1-propylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-oxazolium hydrochloride [Step 1] Preparation of tert-butyl 4-[(6-cyanopyridin-3-yl)oxy]piperidine-1-carboxylate In a mixture of tert-butyl 4-hydroxypiperidine-1-carboxylate (7.42 g) and N,N-dimethylformamide (50 mL), sodium hydride (60%, dispersed in liquid paraffin, 1.47 g) was added under ice-cooling and stirred for 10 minutes. Then, 5-fluoropyridine-2-carboxynitrile (3.0 g) was added and stirred for 1 hour. Water was added to the reaction mixture under ice-cooling, and the mixture was diluted with ethyl acetate. After washing with water and saturated brine, the solution was dried over anhydrous sodium sulfate. The solvent was removed by vacuum distillation, and the precipitate was filtered off, dried, and the title compound (6.0 g) was obtained.

[0179] MS (m / z): 248.2 [M- t Bu+H] + .

[0180] [Step 2] Preparation of 5-(piperidin-4-yloxy)pyridine-2-carboxylonite hydrochloride In a mixture of 6.0 g of tert-butyl 4-[(6-cyanopyridin-3-yl)oxy]piperidine-1-carboxylate and 20 mL of methanol, 50 mL of 4 M ethyl hydrochloride solution was added at room temperature and the mixture was stirred overnight. The solvent was removed by vacuum distillation, the precipitate was filtered off, washed with ethyl acetate, and dried to give the title compound (4.5 g).

[0181] MS (m / z): 204.2[M+H] + .

[0182] [Step 3] Preparation of 5-[(1-propylpiperidin-4-yl)oxy]pyridine-2-carboxynitrile In a mixture of 5-(piperidin-4-yloxy)pyridine-2-carboxynitrile hydrochloride (500 mg), N,N-dimethylformamide (1 mL), and diisopropylethylamine (1.08 mL), 1-bromopropane (385 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. The mixture was purified by silica gel column chromatography to obtain the title compound (300 mg).

[0183] MS (m / z): 246.2[M+H] + .

[0184] [Step 4] Preparation of 3-{5-[(1-propylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (260 mg) was obtained by replacing 5-[(1-propylpiperidin-4-yl)oxy]pyridine-2-carboxylonitrile (300 mg) with 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile (300 mg).

[0185] MS (m / z): 305.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.50 (br, 1H), 7.96 (d, 1H), 7.71 (dd, 1H), 5.05-4.7 7 (m, 1H), 3.63-2.95 (m, 6H), 2.33-1.95 (m, 4H), 1.79-1.67 (m, 2H), 0.92 (t, 3H).

[0186] Example 16 3-(5-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2, 4-Oxadiazole-5-one hydrochloride [Step 1] Preparation of 5-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}pyridine-2-carboxynitrile In a mixture of 5-(piperidin-4-yloxy)pyridine-2-carboxynitrile hydrochloride (500 mg), N,N-dimethylformamide (1 mL), and diisopropylethylamine (1.08 mL) obtained in step 2 of Example 15, (bromomethyl)cyclopropane (422 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. Purification was performed by silica gel column chromatography to obtain the title compound (300 mg).

[0187] MS (m / z): 258.2[M+H] + .

[0188] [Step 2] Preparation of 3-(5-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride) By following steps 2 and 3 of Example 1, the title compound (310 mg) was obtained by replacing 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile with 5-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}pyridine-2-carboxylonitrile (300 mg).

[0189] MS (m / z): 317.0[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.43 (d, 1H), 7.89 (d, 1H), 7.64 (dd, 1H), 4.80-4.70 (m, 1H), 3.20-3.05 (m, 2H), 2.94-2.80 (m , 2H), 2.70-2.60 (m, 2H), 2.20-2.05 (m, 2H), 1.94-1.80 (m, 2H), 1.04-0.92 (m, 1H), 0.60-0.48 (m, 2H), 0.28-0.15 (m, 2H).

[0190] Example 17 3-{5-[(1-propylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-Azolium In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (150 mg), N,N-dimethylformamide (2.15 mL), and diisopropylethylamine (0.37 mL) obtained in step 4 of Example 14, 1-bromopropane (0.12 mL) was added sequentially at room temperature, and the mixture was stirred at 80 °C for 4 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (42 mg).

[0191] MS (m / z): 319.1[M+H] + .

[0192] Example 18 3-{5-[2-(2,3-dihydro-1H-isoindol-2-yl)ethoxy]pyridin-2-yl}-4,5-dihydro- 1,2,4-Oxadiazole-5-one hydrochloride [Step 1] Preparation of 5-[2-(2,3-dihydro-1H-isoindol-2-yl)ethoxy]pyridine-2-carboxynitrile By following the method in step 1 of Example 1, 2-(2,3-dihydro-1H-isoindol-2-yl)ethane-1-ol (122 mg) was used instead of (1-ethylpiperidin-4-yl)methanol to obtain the title compound (112 mg).

[0193] MS (m / z): 266.2[M+H] + .

[0194] [Step 2] Preparation of 3-{5-[2-(2,3-dihydro-1H-isoindol-2-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (76 mg) was obtained by using 5-[2-(2,3-dihydro-1H-isoindol-2-yl)ethoxy]pyridine-2-carboxylonitrile (112 mg) instead of 5-[1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile (112 mg) obtained in step 1 of Example 18.

[0195] MS (m / z): 325.1[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.52 (d, 1H), 8.03 (d, 1H), 7.65 (dd, 1H), 7.45-7.38 (m, 4H), 4.60 (t, 2H), 3.99 (t, 2H), 3.29 (s, 4H) Elemental analysis values ​​(in C) 17 H 16 (Based on N4O3・HCl・0.2H2O) Calculated values ​​(%): C: 56.03, H: 4.81, N: 15.38 Measured values ​​(%) C: 56.01, H: 4.64, N: 15.44.

[0196] Example 19 3-{5-[2-(1,2,3,4-tetrahydroisoquinoline-2-yl)ethoxy]pyridin-2-yl}-4,5-dihydro- 1,2,4-Oxadiazole-5-one hydrochloride [Step 1] Preparation of 5-[2-(1,2,3,4-tetrahydroisoquinoline-2-yl)ethoxy]pyridine-2-carboxynitrile By following the method in step 1 of Example 1, 2-(1,2,3,4-tetrahydroisoquinoline-2-yl)ethane-1-ol (174 mg) was used instead of (1-ethylpiperidin-4-yl)methanol to obtain the title compound (164 mg).

[0197] MS (m / z): 280.2[M+H] + .

[0198] [Step 2] Preparation of 3-{5-[2-(1,2,3,4-tetrahydroisoquinoline-2-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (30 mg) was obtained by using 5-[2-(1,2,3,4-tetrahydroisoquinoline-2-yl)ethoxy]pyridine-2-carboxylonitrile (162 mg) instead of 5-[1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile (162 mg) obtained in step 1 of Example 19.

[0199] MS (m / z): 339.1[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.42 (d, 1H), 7.95 (d, 1H), 7.56 (dd, 1H), 7.18-7.05 (m, 4H), 4.42 (t, 2H), 3.94 (s, 2H), 3.18 (t, 2H), 3.10-3.04 (m, 2H), 3.04-2.96 (m, 2H).

[0200] Example 20 4-({[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}methane ethyl piperidine-1-carboxylate In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (100 mg), N,N-dimethylformamide (0.57 mL), and diisopropylethylamine (0.24 mL) obtained in step 4 of Example 14, ethyl chloroformate (0.027 mL) was added sequentially at room temperature and stirred for 15 minutes. The mixture was diluted with water, 2 M hydrochloric acid was added, the precipitate was filtered off, and dried to give the title compound (83 mg).

[0201] MS (m / z): 349.2[M+H] + Elemental analysis values ​​(in C) 16 H 20 (N4O5 calculation) Calculated values ​​(%): C: 55.17, H: 5.79, N: 16.08 Measured values ​​(%) C: 55.07, H: 5.82, N: 16.07.

[0202] Example 21 3-(5-{3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy}pyridin-2-yl)-4,5-dihydro-1, 2,4-Oxadiazole-5-one hydrochloride [Step 1] Preparation of 5-{3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy}pyridine-2-carboxylon In a mixture of 3-[4-(2-fluorophenyl)piperazin-1-yl]propane-1-ol (351 mg) and N,N-dimethylformamide (3 mL), sodium hydride (60%, dispersed in liquid paraffin, 59 mg) was added sequentially at room temperature and stirred for 15 minutes. Then, 5-fluoropyridine-2-carboxynitrile (120 mg) was added and the mixture was stirred overnight. Water was added to the reaction mixture, and the solution was purified by silica gel column chromatography to give the title compound (270 mg).

[0203] MS (m / z): 341.1[M+H] + .

[0204] [Step 2] Preparation of 5-{3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy}-N'-hydroxypyridine-2-carboximide amide In a mixture of hydroxylamine hydrochloride (480 mg) and dimethyl sulfoxide (5 mL), KO was added sequentially at room temperature. t Bu (712 mg) was stirred for 10 minutes. 5-{3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy}pyridine-2-carboxynitrile (270 mg) was added, and the mixture was stirred at room temperature for 4 hours. Water was added to the reaction mixture, and the solution was purified by silica gel column chromatography to give the title compound (160 mg).

[0205] MS (m / z): 374.2[M+H] + .

[0206] [Step 3] Preparation of 3-(5-{3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride) In a mixture of 5-{3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy}-N'-hydroxypyridine-2-carboximide amide (160 mg), tetrahydrofuran (5 mL), and DBU (0.096 mL), CDI (104 mg) was added at room temperature and the mixture was stirred for 5 hours. Water was added to the reaction mixture, and hydrochloric acid was added dropwise to adjust the pH to acidic. The solution was purified by silica gel column chromatography to obtain the title compound (75 mg).

[0207] MS (m / z): 400.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.39 (d, 1H), 7.88 (d, 1H), 7.57 (dd, 1H), 7.15-6.92 (m, 4H), 4 .20 (t, 2H), 3.05-2.98 (m, 4H), 2.60-2.56 (m, 4H), 2.55-2.48 (m, 2H), 1.99-1.92 (m, 2H).

[0208] Example 22 3-{5-[2-(4-phenylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa Diazole-5-one hydrochloride [Step 1] Preparation of 5-[2-(4-phenylpiperazin-1-yl)ethoxy]pyridine-2-carboxylon By following the method in step 1 of Example 1, 2-(4-phenylpiperazin-1-yl)ethane-1-ol (50 mg) was used instead of (1-ethylpiperidin-4-yl)methanol to obtain the title compound (62 mg).

[0209] MS (m / z): 309.2[M+H] + .

[0210] [Step 2] Preparation of 3-{5-[2-(4-phenylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following the methods of steps 2 and 3 of Example 1, the title compound (45 mg) was obtained by using 5-[2-(4-phenylpiperazin-1-yl)ethoxy]pyridine-2-carboxylonitrile (62 mg) instead of 5-[1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile (62 mg) obtained in step 1 of Example 22.

[0211] MS (m / z): 368.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.43 (d, 1H), 7.91 (d, 1H), 7.61 (dd, 1H), 7.23-7.16 (m, 2H), 6.96-6.91 (m, 2H) , 6.78-6.74 (m, 1H), 4.31 (t, 2H), 4.20-4.00 (br, 1H), 3.16-3.12 (m, 4H), 2.80 (t, 2H), 2.68-2.92 (m, 4H).

[0212] Example 23 3-{5-[3-(piperidin-1-yl)propoxy]pyrimidin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto-4-methylbenzene-1-sulfonate [Step 1] Preparation of 5-[3-(piperidin-1-yl)propoxy]pyrimidine-2-carboxynitrile In a mixture of 175 mg of 3-(piperidin-1-yl)propane-1-ol and 1.6 mL of N,N-dimethylformamide, sodium hydride (60%, dispersed in liquid paraffin, 49 mg) was added under ice-cooling and stirred for 15 minutes. Then, 100 mg of 5-fluoropyrimidin-2-carboxynitrile was added and the mixture was stirred for 2 hours under ice-cooling. Water was added to the reaction mixture under ice-cooling, and the mixture was diluted with ethyl acetate. After washing with water and saturated brine, the solution was dried over anhydrous sodium sulfate. The solvent was removed by vacuum distillation, and the residue was purified by silica gel column chromatography to give the title compound (69 mg).

[0213] MS (m / z): 247.1[M+H] + .

[0214] [Step 2] Preparation of N-hydroxy-5-[3-(piperidin-1-yl)propoxy]pyrimidine-2-carboximide amide In a mixture of hydroxylamine hydrochloride (97 mg) and ethanol (1.4 mL), 0.7 mL of 2 M sodium hydroxide aqueous solution was added, and the mixture was stirred at room temperature for 10 minutes. 5-[3-(piperidin-1-yl)propoxy]pyrimidine-2-carboxynitrile (69 mg) was added to the reaction mixture, and the mixture was stirred for 4 hours. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (58 mg).

[0215] MS (m / z): 280.1[M+H] + .

[0216] [Step 3] Preparation of 3-{5-[3-(piperidin-1-yl)propoxy]pyrimidin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one 4-methylbenzene-1-sulfonate In a mixture of N-hydroxy-5-[3-(piperidin-1-yl)propoxy]pyrimidine-2-carboximide amide (58 mg), tetrahydrofuran (1 mL), and DBU (0.046 mL), CDI (51 mg) was added at room temperature and the mixture was stirred for 15 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (316 mg) was added dropwise to adjust the pH to acidity. Purification was performed by silica gel column chromatography to give the title compound (39 mg).

[0217] MS (m / z): 306.1[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.64 (s, 2H), 7.69 (d, 2H), 7.22 (d, 2H), 4.35 (t, 2H), 3.80-3 .50 (m, 2H), 3.40-3.26 (m, 2H), 3.10-2.80 (m, 2H), 2.42-2.26 (m, 5H), 2.10-1.40 (m, 6H).

[0218] Example 24 3-{6-[3-(piperidin-1-yl)propoxy]pyridazine-3-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto Hydrochloride [Step 1] Preparation of 6-[3-(piperidin-1-yl)propoxy]pyridazine-3-carboxynitrile In a mixture of 770 mg of 3-(piperidin-1-yl)propane-1-ol and 5 mL of N,N-dimethylformamide, sodium hydride (60%, dispersed in liquid paraffin, 215 mg) was added, and the mixture was stirred at room temperature for 30 minutes. Then, 500 mg of 6-chloropyridazine-3-carboxynitrile was added, and the mixture was stirred overnight at room temperature. Water was added to the reaction mixture under ice-cooling, and the mixture was purified by silica gel column chromatography to give the title compound (300 mg).

[0219] MS (m / z): 247.2[M+H] + .

[0220] [Step 2] Preparation of N-hydroxy-6-[3-(piperidin-1-yl)propoxy]pyridazine-3-carboximide amide In a mixture of hydroxylamine hydrochloride (510 mg) and ethanol (5 mL), 3.04 mL of 2 M sodium hydroxide aqueous solution was added, and the mixture was stirred at room temperature for 30 minutes. 6-[3-(piperidin-1-yl)propoxy]pyridazine-3-carboxynitrile (300 mg) was added to the reaction mixture, and the mixture was stirred overnight. Water was added to the reaction mixture, the precipitate was filtered off, and dried to give the title compound (227 mg).

[0221] MS (m / z): 280.2[M+H] + .

[0222] [Step 3] Preparation of 3-{6-[3-(piperidin-1-yl)propoxy]pyridazine-3-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride In a mixture of N-hydroxy-6-[3-(piperidin-1-yl)propoxy]pyridazine-3-carboximide amide (227 mg), tetrahydrofuran (5 mL), and DBU (0.182 mL), CDI (198 mg) was added at room temperature and the mixture was stirred overnight. Water was added to the reaction mixture, and hydrochloric acid was added dropwise to adjust the pH to acidic. The mixture was purified by silica gel column chromatography to give the title compound (125 mg).

[0223] MS (m / z): 306.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.13 (d, 1H), 7.43 (d, 1H), 4.62 (t, 2H), 3.58-3.25 (m, 4H), 3.20 (t, 2H), 2.32-2.22 (m, 2H), 1.86-1.25 (m, 6H) Elemental analysis values ​​(in C) 14 H 19 (Based on N5O3・HCl・0.1H2O) Calculated values ​​(%): C: 48.94, H: 5.93, N: 20.38 Measured values ​​(%) C: 48.84, H: 6.08, N: 20.39.

[0224] Example 25 3-(5-{[3-(piperidin-1-yl)propyl]thioalkyl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxa Diazol-5-one 4-methylbenzene-1-sulfonate [Step 1] Preparation of 5-({3-[(tert-butyldimethylsilyl)oxy]propyl}thioalkyl)pyridine-2-carboxylon In a mixture of 3-thioalkylpropane-1-ol (1 g), N,N-dimethylformamide (5 mL), and sodium carbonate (2.3 g), 5-fluoropyridine-2-carboxynitrile (1.5 g) was added, and the mixture was heated and stirred at 50 °C for 3 hours. The reaction mixture was then brought to room temperature, and imidazole (2.24 g) and tert-butyl(chloro)dimethylsilane (2.13 g) were added, followed by stirring overnight. Purification was performed by silica gel column chromatography to obtain the title compound (800 mg).

[0225] MS (m / z): 309.2[M+H] + .

[0226] [Step 2] Preparation of 3-[5-({3-[(tert-butyldimethylsilyl)oxy]propyl}thioalkyl)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one] By following steps 2 and 3 of Example 7, the title compound (950 mg) was obtained by replacing 5-[3-(piperidin-1-yl)propoxy]pyridine-2-carboxylonitrile] with the 5-({3-[(tert-butyldimethylsilyl)oxy]propyl}thioalkyl)pyridine-2-carboxylonitrile) obtained in step 1 of Example 25.

[0227] MS (m / z): 368.1[M+H] + .

[0228] [Step 3] Preparation of 3-{5-[(3-hydroxypropyl)thioalkyl]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one 3-[5-({3-[(tert-butyldimethylsilyl)oxy]propyl}thioalkyl)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (950 mg) was added to a 4 M ethyl hydrochloride solution (6.46 mL), and the mixture was stirred at room temperature for 1 hour. The precipitate was filtered off, dried, and the title compound (700 mg) was obtained.

[0229] MS (m / z): 252.1[M+H] + .

[0230] [Step 4] Preparation of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]thioalkyl}propyl 4-methylbenzene-1-sulfonate In a mixture of 3-{5-[(3-hydroxypropyl)thioalkyl]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (200 mg) and pyridine (3 mL), 4-methylbenzene-1-sulfonyl chloride (256 mg) was added, and the mixture was stirred for 1 hour. Hexane was added to the reaction solution, the precipitate was filtered off, and dried to give the title compound (280 mg).

[0231] MS (m / z): 408.2[M+H] + .

[0232] [Step 5] Preparation of 3-(5-{[3-(piperidin-1-yl)propyl]thioalkyl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one 4-methylbenzene-1-sulfonate) In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]thioalkyl}propyl 4-methylbenzene-1-sulfonate (80 mg), N,N-dimethylformamide (0.5 mL), and sodium iodide (88 mg), piperidine (50 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. Hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (35 mg).

[0233] MS (m / z): 321.0[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.61 (s, 1H), 7.94-7.82 (m, 2H), 7.47 (d, 2H), 7.11 (d, 2H), 3.20-2.92 (m, 6H), 2.28 (s, 3H), 2.00-1.88 (m, 4H), 1.72-1.42 (m, 6H).

[0234] Example 26 3-(5-{[3-(pyrrolidone-1-yl)propyl]thioalkyl}pyridin-2-yl)-4,5-dihydro-1,2,4- Oxadiazole-5-one 4-methylbenzene-1-sulfonate In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]thioalkyl}propyl 4-methylbenzene-1-sulfonate (80 mg), sodium iodide (88 mg), diisopropylethylamine (0.1 mL), and N,N-dimethylformamide (0.5 mL), pyrrolidine (42 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (187 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (15 mg).

[0235] MS (m / z): 307.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.66 (d, 1H), 7.98 (dd, 1H), 7.89 (d, 1H), 7.47 (d, 2H), 7.11 (d, 2H), 3.40-3.15 (m, 8H), 2.28 (s, 3H), 1.99-1.84 (m, 6H).

[0236] Example 27 3-(5-{[3-(azacycloheptan-1-yl)propyl]thioalkyl}pyridin-2-yl)-4,5-dihydro-1, 2,4-Oxadiazole-5-one hydrochloride By using azircycloheptane (58 mg) instead of pyrrolidine according to the method of Example 26, the title compound (73 mg) was obtained.

[0237] MS (m / z): 335.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.47 (s, 1H), 7.72-7.64 (m, 2H), 3.15-2.95 (m, 8H), 1.95-1.85 (m, 2H), 1.75-1.45 (m, 8H).

[0238] Example 28 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}piperazine Phenyl 1-carboxylic acid ester [Step 1] Preparation of 4-[(6-cyanopyridin-3-yl)oxy]piperidine-1-carboxylic acid phenyl ester To the mixture of 5-(piperidin-4-yloxy)pyridine-2-carboxynitrile hydrochloride (500 mg), N,N-dimethylformamide (5 mL), and diisopropylethylamine (1.08 mL) obtained in step 2 of Example 15, phenyl chloroformate (380 mg) was added, and the mixture was stirred at room temperature for 1 hour. Purification was performed by silica gel column chromatography to obtain the title compound (400 mg).

[0239] MS (m / z): 324.0[M+H] + .

[0240] [Step 2] Preparation of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}piperidine-1-carboxylic acid phenyl ester By following steps 2 and 3 of Example 1, the title compound (370 mg) was obtained by using 4-[(6-cyanopyridin-3-yl)oxy]piperidine-1-carboxylic acid phenyl ester (400 mg) instead of 5-[(1-ethylpiperidine-4-yl)methoxy]pyridine-2-carboxylonitrile]piperidine-1-carboxylic acid phenyl ester obtained in step 1 of Example 28.

[0241] MS (m / z): 383.0[M+H] + Elemental analysis values ​​(in C) 19 H 18 (N4O5 calculation) Calculated values ​​(%): C: 59.68, H: 4.75, N: 14.65 Measured values ​​(%) C: 59.64, H: 4.58, N: 14.70.

[0242] Example 29 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}piperazine Ethyl 1-pyridinecarboxylate [Step 1] Preparation of ethyl 4-[(6-cyanopyridin-3-yl)oxy]piperidine-1-carboxylate In a mixture of 5-(piperidin-4-yloxy)pyridine-2-carboxynitrile hydrochloride (500 mg), N,N-dimethylformamide (5 mL), and diisopropylethylamine (1.08 mL) obtained in step 2 of Example 15, ethyl chloroformate (340 mg) was added, and the mixture was stirred at room temperature for 1 hour. Purification was performed by silica gel column chromatography to obtain the title compound (400 mg).

[0243] MS (m / z): 276.0[M+H] + .

[0244] [Step 2] Preparation of ethyl 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}piperidine-1-carboxylate By following steps 2 and 3 of Example 1, the title compound (180 mg) was obtained by using ethyl 4-[(6-cyanopyridin-3-yl)oxy]piperidine-1-carboxylate (400 mg) instead of 5-[(1-ethylpiperidine-4-yl)methoxy]pyridine-2-carboxylonitrile (400 mg) in step 1 of Example 29.

[0245] MS (m / z): 335.0[M+H] + Elemental analysis values ​​(in C) 15 H 18 (N4O5 calculation) Calculated values ​​(%): C: 53.89, H: 5.43, N: 16.76 Measured values ​​(%) C: 53.81, H: 5.37, N: 16.71.

[0246] Example 30 3-{5-[(1-ethylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-oxazolium hydrochloride [Step 1] Preparation of 5-[(1-ethylpiperidin-4-yl)oxy]pyridine-2-carboxynitrile In a mixture of 1-ethylpiperidin-4-ol (206 mg) and N,N-dimethylformamide (3 mL), sodium hydride (60%, dispersed in liquid paraffin, 64 mg) was added sequentially at room temperature and stirred for 15 minutes. Then, 5-fluoropyridine-2-carboxynitrile (130 mg) was added and the mixture was stirred overnight. Water was added to the reaction mixture, and the solution was purified by silica gel column chromatography to give the title compound (240 mg).

[0247] MS (m / z): 232.2[M+H] + .

[0248] [Step 2] Preparation of 5-[(1-ethylpiperidin-4-yl)oxy]-N'-hydroxypyridine-2-carboximide amide In a mixture of hydroxylamine hydrochloride (577 mg) and dimethyl sulfoxide (5 mL), KO was added sequentially at room temperature. t Bu (931 mg) was stirred for 10 minutes. 5-[(1-ethylpiperidin-4-yl)oxy]pyridine-2-carboxynitrile (240 mg) was added, and the mixture was stirred at room temperature for 4 hours. Water was added to the reaction mixture, and the solution was purified by silica gel column chromatography to give the title compound (260 mg).

[0249] MS (m / z): 265.1[M+H] + .

[0250] [Step 3] Preparation of 3-{5-[(1-ethylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride In a mixture of 5-[(1-ethylpiperidin-4-yl)oxy]-N'-hydroxypyridine-2-carboximide amide (260 mg), tetrahydrofuran (5 mL), and DBU (0.22 mL), CDI (239 mg) was added at room temperature and the mixture was stirred overnight. Water was added to the reaction mixture, and hydrochloric acid was added dropwise to adjust the pH to acidic. The solution was purified by silica gel column chromatography to give the title compound (160 mg).

[0251] MS (m / z): 291.1[M+H] + 1H-NMR (400MHz, DMSO-d6) δ: 8.44 (d, 1H), 7.91 (d, 1H), 7.65 (dd, 1H), 4.80-4.74 (m, 1H), 4.25-3.8 5 (m, 2H), 3.60-3.00 (m, 2H), 2.88-2.74 (m, 3H), 2.16-2.07 (m, 2H), 1.92-1.82 (m, 2H), 1.15 (t, 3H) Elemental analysis values ​​(in C) 14 H 18 (N4O3·HCl) Calculated values ​​(%): C: 51.46, H: 5.86, N: 17.15 Measured values ​​(%) C: 51.45, H: 6.19, N: 17.21.

[0252] Example 31 3-{5-[(1-butylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-oxazolium hydrochloride [Step 1] Preparation of 5-[(1-Butylpiperidin-4-yl)oxy]pyridine-2-carboxynitrile In a mixture of 5-(piperidin-4-yloxy)pyridine-2-carboxynitrile hydrochloride (500 mg), N,N-dimethylformamide (1 mL), and diisopropylethylamine (1.08 mL) obtained in step 2 of Example 15, 1-bromobutane (429 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. Purification was performed by silica gel column chromatography to obtain the title compound (190 mg).

[0253] MS (m / z): 260.1[M+H] + .

[0254] [Step 2] Preparation of 3-{5-[(1-butylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 1, the title compound (220 mg) was obtained by using 5-[(1-butylpiperidin-4-yl)oxy]pyridine-2-carboxylonitrile (190 mg) instead of 5-[1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile (190 mg).

[0255] MS (m / z): 319.1[M+H] + 1H-NMR (400MHz, DMSO-d6) δ: 8.49 (d, 1H), 7.96 (d, 1H), 7.72 (dd, 1H), 5.10-4.70 (br, 1H), 3.65-3.20 (m , 4H), 3.05 (t, 2H), 2.30-2.18 (m, 2H), 2.14-1.95 (m, 2H), 1.74-1.65 (m, 2H), 1.31 (dt, 2H), 0.92 (t, 3H) Elemental analysis values ​​(in C) 16 H 22 (Based on N4O3・HCl・1H2O) Calculated values ​​(%): C: 51.54, H: 6.76, N: 15.03 Measured values ​​(%) C: 51.24, H: 7.00, N: 14.97.

[0256] Example 32 3-{5-[(1-pentylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-oxazolium hydrochloride [Step 1] Preparation of 5-[(1-pentylpiperidin-4-yl)oxy]pyridine-2-carboxynitrile In a mixture of 5-(piperidin-4-yloxy)pyridine-2-carboxynitrile hydrochloride (400 mg), N,N-dimethylformamide (1 mL), and diisopropylethylamine (0.86 mL) obtained in step 2 of Example 15, 1-bromopentane (504 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. Purification was performed by silica gel column chromatography to obtain the title compound (300 mg).

[0257] MS (m / z): 274.2[M+H] + .

[0258] [Step 2] Preparation of 3-(5-{[1-(cyclobutylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride) By following steps 2 and 3 of Example 1, the title compound (280 mg) was obtained by replacing 5-[(1-pentylpiperidin-4-yl)oxy]pyridine-2-carboxylonitrile (300 mg) with 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile (300 mg).

[0259] MS (m / z): 333.1[M+H] + 1H-NMR (400MHz, DMSO-d6) δ: 10.50 (br, 1H), 8.50 (d, 1H), 7.96 (d, 1H), 7.72 (dd, 1H), 5.02-4.98 (br, 1H), 4.85-4.73 (m, 1H), 3.60-3.32 (m, 4H), 3.18-2.97 (m, 4H), 2.34-1.92 (m, 2H), 1.76-1.65 (m, 2H), 1.38-1.24 (m, 4H), 0.89 (t, 3H) Elemental analysis values ​​(in C) 17 H 24 (Based on N4O3・HCl・0.3H2O) Calculated values ​​(%): C: 54.56, H: 6.89, N: 14.97 Measured values ​​(%) C: 54.51, H: 6.97, N: 15.02.

[0260] Example 33 3-(5-{[1-(cyclobutylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2, 4-Oxadiazole-5-one hydrochloride [Step 1] Preparation of 5-{[1-(cyclobutylmethyl)piperidin-4-yl]oxy}pyridine-2-carboxynitrile In a mixture of 5-(piperidin-4-yloxy)pyridine-2-carboxynitrile hydrochloride (500 mg), N,N-dimethylformamide (1 mL), and diisopropylethylamine (1.08 mL) obtained in step 2 of Example 15, (bromomethyl)cyclobutane (466 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. Purification was performed by silica gel column chromatography to obtain the title compound (113 mg).

[0261] MS (m / z): 272.1[M+H] + .

[0262] [Step 2] Preparation of 3-(5-{[1-(cyclobutylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride) By following steps 2 and 3 of Example 1, the title compound (90 mg) was obtained by replacing 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile with 5-{[1-(cyclobutylmethyl)piperidin-4-yl]oxy}pyridine-2-carboxylonitrile (113 mg).

[0263] MS (m / z): 331.0[M+H] + 1H-NMR (400MHz, DMSO-d6) δ: 8.49 (d, 1H), 7.96 (d, 1H), 7.71 (dd, 1H), 5.10-4.70 (br, 1H), 3.62-3.20 (m, 4H), 3.14 (d, 2H), 2.86-2.72 (m, 1H), 2.30-1.55 (m, 11H) Elemental analysis values ​​(in C) 17 H 22 (Based on N4O3・HCl・0.5H2O) Calculated values ​​(%): C: 54.33, H: 6.44, N: 14.91 Measured values ​​(%) C: 53.99, H: 6.45, N: 14.90.

[0264] Example 34 3-(5-{[1-(propane-2-yl)piperidin-4-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1, 2,4-Oxadiazol-5-one [Step 1] Preparation of 5-{[1-(propane-2-yl)piperidin-4-yl]methoxy}pyridine-2-carboxynitrile In a mixture of [1-(propane-2-yl)piperidin-4-yl]methanol (386 mg) and N,N-dimethylformamide (3 mL), sodium hydride (60%, dispersed in liquid paraffin, 98 mg) was added sequentially at room temperature and stirred for 15 minutes. Then, 5-fluoropyridine-2-carboxynitrile (200 mg) was added and the mixture was stirred overnight. Water was added to the reaction mixture, and the solution was purified by silica gel column chromatography to give the title compound (300 mg).

[0265] MS (m / z): 260.1[M+H] + .

[0266] [Step 2] Preparation of N'-hydroxy-5-{[1-(propane-2-yl)piperidin-4-yl]methoxy}pyridine-2-carboximide amide In a mixture of hydroxylamine hydrochloride (460 mg) and dimethyl sulfoxide (5 mL), KO was added sequentially at room temperature. t Bu (649 mg) was stirred for 10 minutes. 5-{[1-(propane-2-yl)piperidin-4-yl]methoxy}pyridine-2-carboxynitrile (300 mg) was added, and the mixture was stirred at room temperature for 4 hours. Water was added to the reaction mixture, and the solution was purified by silica gel column chromatography to give the title compound (280 mg).

[0267] MS (m / z): 293.2[M+H] + .

[0268] [Step 3] Preparation of 3-(5-{[1-(propane-2-yl)piperidin-4-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one) In a mixture of N'-hydroxy-5-{[1-(propane-2-yl)piperidin-4-yl]methoxy}pyridine-2-carboximide amide (280 mg), tetrahydrofuran (5 mL), and DBU (0.172 mL), CDI (202 mg) was added at room temperature and stirred overnight. Water was added to the reaction mixture, and hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (250 mg).

[0269] MS (m / z): 319.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.33 (d, 1H), 7.82 (d, 1H), 7.49 (dd, 1H), 4.15-4.00 (br, 1H), 4.00 ( d, 2H), 3.30-3.00 (m, 4H), 2.70-2.55 (m, 2H), 2.00-1.85 (m, 3H), 1.51-1.41 (m, 2H), 1.12 (d, 6H) Elemental analysis values ​​(in C) 16 H 22 (Based on N4O3・0.3H2O) Calculated values ​​(%): C: 59.35, H: 7.04, N: 17.30 Measured values ​​(%) C: 59.11, H: 7.10, N: 17.27.

[0270] Example 35 3-{5-[(1-butylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-Azolium In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (150 mg), N,N-dimethylformamide (2.15 mL), water (2.15 mL), and diisopropylethylamine (0.37 mL), 1-bromobutane (0.138 mL) was added sequentially at room temperature, and the mixture was heated and stirred at 80 °C for 4 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (13 mg).

[0271] MS (m / z): 333.1[M+H] + .

[0272] Example 36 3-(5-{[1-(cyclopropylmethyl)piperidin-4-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1, 2,4-Oxadiazole-5-one hydrochloride In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (150 mg) and N,N-dimethylformamide (1 mL), (bromomethyl)cyclopropane (290 mg), tetrabutylammonium iodide (232 mg), and 10 M sodium hydroxide aqueous solution (0.13 mL) were added, and the mixture was heated and stirred at 80 °C for 3 hours. Hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (30 mg).

[0273] MS (m / z): 331.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.40 (d, 1H), 7.89 (d, 1H), 7.57 (dd, 1H), 4.04 (d, 2H), 3.45 (d, 1H), 2.85-2.75 (m, 3H), 2.10-1.85 (m, 3H), 1.65 (dd, 2H), 1.25 (dd, 2H), 1.10-1.00 (m, 1H), 0.64-0.55 (m, 2H), 0.35-0.27 (m, 2H).

[0274] Example 37 3-{5-[(1-benzylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-Azolium In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (30 mg), N,N-dimethylformamide (0.43 mL), water (0.43 mL), and diisopropylethylamine (0.074 mL), bromomethylbenzene (15 mg) was added, and the mixture was stirred at room temperature for 2 hours. Purification was performed by silica gel column chromatography to obtain the title compound (7 mg).

[0275] MS (m / z): 367.3[M+H] + .

[0276] Example 38 3-[5-({1-[(2-ethylphenyl)methyl]piperidin-4-yl}methoxy)pyridin-2-yl]-4,5- Dihydro-1,2,4-oxadiazol-5-one In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (150 mg), N,N-dimethylformamide (2.15 mL), water (2.15 mL), and diisopropylethylamine (0.372 mL), 1-(bromomethyl)-2-ethylbenzene (90 mg) was added, and the mixture was stirred overnight at room temperature. Purification was performed by silica gel column chromatography to obtain the title compound (67 mg).

[0277] MS (m / z): 395.1[M+H] + .

[0278] Example 39 3-{5-[(1-{[2-(trifluoromethyl)phenyl]methyl}piperidin-4-yl)methoxy]pyridine-2- 4,5-dihydro-1,2,4-oxadiazol-5-one In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (150 mg), N,N-dimethylformamide (2.15 mL), water (2.15 mL), and diisopropylethylamine (0.372 mL), 1-(bromomethyl)-2-(trifluoromethyl)benzene (108 mg) was added, and the mixture was stirred overnight at room temperature. Purification was performed by silica gel column chromatography to obtain the title compound (102 mg).

[0279] MS (m / z): 435.0[M+H] + .

[0280] Example 40 3-[5-({1-[(3-fluorophenyl)methyl]piperidin-4-yl}methoxy)pyridin-2-yl]-4,5-di Hydro-1,2,4-oxadiazol-5-one In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (150 mg), N,N-dimethylformamide (2.15 mL), water (2.15 mL), and diisopropylethylamine (0.37 mL), 1-(bromomethyl)-3-fluorobenzene (85 mg) was added, and the mixture was stirred at room temperature for 2 hours. Purification was performed by silica gel column chromatography to obtain the title compound (22 mg).

[0281] MS (m / z): 385.0[M+H] + .

[0282] Example 41 3-[5-({1-[(3-bromophenyl)methyl]piperidin-4-yl}methoxy)pyridin-2-yl]-4,5-di Hydro-1,2,4-oxadiazol-5-one In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (120 mg), N,N-dimethylformamide (1.72 mL), water (1.72 mL), and diisopropylethylamine (0.30 mL), 1-bromo-3-(bromomethyl)benzene (90 mg) was added, and the mixture was stirred at room temperature for 2 hours. Purification was performed by silica gel column chromatography to obtain the title compound (24 mg).

[0283] MS (m / z): 445.2[M+H] + .

[0284] Example 42 3-{5-[(1-acetylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa diazol-5-one In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (100 mg), N,N-dimethylformamide (1 mL), acetic acid (25 mg), and diisopropylethylamine (0.27 mL) obtained in step 4 of Example 14, HATU (146 mg) was added, and the mixture was stirred at room temperature for 45 minutes. Purification was performed by silica gel column chromatography to obtain the title compound (59 mg).

[0285] MS (m / z): 319.2[M+H] + .

[0286] Example 43 3-{5-[(1-propionylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa diazol-5-one In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (150 mg), N,N-dimethylformamide (1 mL), propionic acid (46 mg), and diisopropylethylamine (0.40 mL) obtained in step 4 of Example 14, HATU (219 mg) was added, and the mixture was stirred at room temperature for 45 minutes. Purification was performed by silica gel column chromatography to obtain the title compound (99 mg).

[0287] MS (m / z): 333.2[M+H] + .

[0288] Example 44 4-({[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}methane Methyl piperidine-1-carboxylate In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (100 mg), N,N-dimethylformamide (0.57 mL), and diisopropylethylamine (0.24 mL), methyl chloroformate (0.022 mL) was added, and the mixture was stirred at room temperature for 1 hour. Hydrochloric acid was added, the precipitate was filtered off, and dried to give the title compound (61 mg).

[0289] MS (m / z): 335.2[M+H] + Elemental analysis values ​​(in C) 15 H 18 (N4O5 calculation) Calculated values ​​(%): C: 53.89, H: 5.43, N: 16.76 Measured values ​​(%) C: 53.88, H: 5.38, N: 16.82.

[0290] Example 45 4-({[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}methane (2-yl)piperidine-1-carboxylic acid propane-2-yl ester In a mixture of 3-{5-[(piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (100 mg), N,N-dimethylformamide (0.57 mL), and diisopropylethylamine (0.24 mL), propane-2-yl chloroformate (0.039 mL) was added sequentially at room temperature and stirred for 15 minutes. 2 M hydrochloric acid was added, and the mixture was diluted with water. The precipitate was filtered off, dried, and the title compound (69 mg) was obtained.

[0291] MS (m / z): 363.3[M+H] + Elemental analysis values ​​(in C) 17 H 22 (N4O5 calculation) Calculated values ​​(%): C: 56.35, H: 6.12, N: 15.46 Measured values ​​(%) C: 56.13, H: 6.28, N: 15.31.

[0292] Example 46 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} Methyl (ethyl)piperazine-1-carboxylate [Step 1] Preparation of methyl 4-{2-[(6-cyanopyridin-3-yl)oxy]ethyl}piperazine-1-carboxylate In a mixture of 5-[2-(piperazin-1-yl)ethoxy]pyridine-2-carboxynitrile dihydrochloride (220 mg), dichloromethane (2.4 mL), and diisopropylethylamine (0.62 mL) obtained in step 2 of Example 6, methyl chloroformate (0.067 mL) was added, and the mixture was stirred for 2 hours. A saturated sodium bicarbonate solution was added to the reaction mixture, and the solution was purified by silica gel column chromatography to obtain the title compound (194 mg).

[0293] MS (m / z): 291.2[M+H] + .

[0294] [Step 2] Preparation of methyl 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylate The title compound (128 mg) was obtained by replacing 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylonitrile with methyl 4-{2-[(6-cyanopyridin-3-yl)oxy]ethyl}piperazine-1-carboxylate (194 mg) obtained in step 1 of Example 46.

[0295] MS (m / z): 350.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.45 (d, 1H), 7.93 (d, 1H), 7.63 (dd, 1H), 4.28 (t, 2H), 3.58 (s, 3H), 3.40-3.25 (m, 8H), 2.79 (t, 2H) Elemental analysis values ​​(in C) 15 H 19 (N5O5・1H2O) Calculated values ​​(%): C: 49.04, H: 5.76, N: 19.06 Measured values ​​(%) C: 49.45, H: 5.64, N: 19.30.

[0296] Example 47 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} Ethyl (ethyl)piperazine-1-carboxylate [Step 1] Preparation of tert-butyl piperazine-1-carboxylate By following steps 2 and 3 of Example 1, the title compound (3.3 g) was obtained by using 4-{2-[(6-cyanopyridin-3-yl)oxy]ethyl}piperazine-1-carboxylic acid tert-butyl ester (3.73 g) obtained in step 1 of Example 6 instead of 5-[(1-ethylpiperidin-4-yl)methoxy]pyridine-2-carboxylon.

[0297] MS (m / z): 392.1[M+H] + .

[0298] [Step 2] Preparation of 3-{5-[2-(piperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one dihydrochloride In 3.3 g of 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid tert-butyl ester, methanol (40 mL), THF (11 mL), and 4 M dioxane hydrochloride solution (22 mL) were added sequentially at room temperature, and the mixture was stirred overnight. The solvent was removed by vacuum distillation to give the title compound (2.95 g).

[0299] MS (m / z): 292.2[M+H] + .

[0300] [Step 3] Preparation of ethyl piperazine-1-carboxylate (2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylate) In a mixture of 3-{5-[2-(piperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one dihydrochloride (100 mg), N,N-dimethylformamide (0.55 mL), and diisopropylethylamine (0.24 mL), ethyl chloroformate (0.026 mL) was added dropwise under ice-cooling, and the mixture was stirred at room temperature for 1 hour. Hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to give the title compound (64 mg).

[0301] MS (m / z): 364.1[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.40 (d, 1H), 7.95 (d, 1H), 7.53 (dd, 1H), 4.30 (t, 2H) ), 4.12 (q, 2H), 3.58-3.45 (m, 4H), 2.90 (t, 2H), 2.65-2.55 (m, 4H), 1.25 (t, 3H) Elemental analysis values ​​(in C)16 H 21 (N5O5 calculation) Calculated values ​​(%): C: 52.89, H: 5.83, N: 19.27 Measured values ​​(%) C: 52.85, H: 5.89, N: 19.30.

[0302] Example 48 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} ethyl (piperazine-1-carboxylic acid propyl ester) By using propyl chloroformate (0.031 mL) instead of ethyl chloroformate in step 3 of Example 47, the title compound (84 mg) was obtained.

[0303] MS (m / z): 378.2[M+H] + .

[0304] Example 49 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} Ethyl)piperazine-1-propane-2-yl ester By following step 3 of Example 47, using propane-2-yl chloroformate (0.038 mL) instead of ethyl chloroformate, the title compound (61 mg) was obtained.

[0305] MS (m / z): 378.2[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.40 (d, 1H), 7.95 (d, 1H), 7.53 (dd, 1H), 4.90-4.80 (m, 1H), 4.3 0 (t, 2H), 3.55-3.45 (m, 4H), 3.35-3.26 (m, 1H), 2.90 (t, 2H), 2.65-2.55 (m, 4H), 1.24 (d, 6H) Elemental analysis values ​​(in C) 17 H 23 (N5O5 calculation) Calculated values ​​(%): C: 54.10, H: 6.14, N: 18.56 Measured values ​​(%) C: 53.70, H: 6.13, N: 18.47.

[0306] Example 50 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} ethylpiperazine-1-carboxylic acid benzyl ester The title compound (44 mg) was obtained by using benzyl chloroformate (0.039 mL) instead of ethyl chloroformate in step 3 of Example 47.

[0307] MS (m / z): 426.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.44 (d, 1H), 7.92 (d, 1H), 7.62 (dd, 1H), 7.40-7.28 (m , 5H), 5.07 (s, 2H), 4.27 (t, 2H), 3.45-3.33 (m, 4H), 2.78 (t, 2H), 2.55-2.45 (m, 4H) Elemental analysis values ​​(in C) 21 H 23 (Based on N5O5・0.5H2O) Calculated values ​​(%): C: 58.06, H: 5.57, N: 16.12 Measured values ​​(%) C: 57.88, H: 5.49, N: 15.86.

[0308] Example 51 3-{5-[3-(azacycloheptan-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa Diazole-5-one hydrochloride [Step 1] Preparation of 3-(5-fluoropyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one In a mixture of hydroxylamine hydrochloride (4.43 g) and ethanol (50 mL), 2 M sodium hydroxide aqueous solution (28.4 mL) was added, and the mixture was stirred at room temperature for 10 minutes. 5-Fluoropyridine-2-carboxynitrile (4.95 g) was added to the reaction mixture, and the mixture was stirred overnight at room temperature. Water was added to the reaction mixture, the precipitate was filtered off, and dried to give a crude product (6.2 g). Tetrahydrofuran (50 mL), DBU (8.9 mL), and CDI (9.7 g) were added to the crude product at room temperature, and the mixture was stirred for 5 hours. Water was added to the reaction mixture, and hydrochloric acid was added dropwise to adjust the pH to acidic. The precipitate was filtered off, dried, and the title compound (6.3 g) was given.

[0309] MS (m / z): 182.1[M+H] + .

[0310] [Step 2] Preparation of 3-[5-(3-hydroxypropoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one In a mixture of 3-(5-fluoropyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (7 g), propane-1,3-diol (8.82 g), and 1-methylpyrrolidone-2-one (70 mL), KO was added. t Bu (8.67 g) was heated and stirred at 60 °C for 3 hours. Hydrochloric acid was added to the reaction solution under ice cooling for neutralization, and the mixture was purified by silica gel column chromatography to obtain the title compound (3.5 g).

[0311] MS (m / z): 238.1[M+H] + .

[0312] [Step 3] Preparation of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate In a mixture of 3-[5-(3-hydroxypropoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (3.0 g), pyridine (3.07 mL), and dichloromethane (100 mL), p-toluenesulfonic anhydride (4-methylbenzenesulfonyl 4-methylbenzene-1-sulfonate) (6.19 g) was added under ice-cooling, and the mixture was stirred at room temperature for 3 hours. A saturated aqueous solution of ammonium chloride was added to the reaction mixture under ice-cooling, diluted with ethyl acetate, washed with water and saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by vacuum distillation, and the residue was purified by silica gel column chromatography to give the title compound (1.9 g).

[0313] MS (m / z): 392.1[M+H] + .

[0314] [Step 4] Preparation of 3-{5-[4-(azacycloheptane-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (80 mg) and N,N-dimethylformamide (1 mL), azircycloheptane (61 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. The reaction mixture was adjusted to acidity by dropwise addition of hydrochloric acid. Purification was performed by silica gel column chromatography to obtain the title compound (35 mg).

[0315] MS (m / z): 319.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.32 (d, 1H), 7.79 (d, 1H), 7.46 (dd, 1H), 4.15 (t, 2H), 3.00-2.88 (m, 4H), 2.04-1.94 (m, 2H), 1.75-1.52 (m, 10H).

[0316] Example 52 3-{5-[2-(azacycloheptan-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa Diazol-5-one 4-methylbenzene-1-sulfonate [Step 1] Preparation of 2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl 4-methylbenzene-1-sulfonate By following steps 1, 2, and 3 of Example 51, ethane-1,2-diol (3.4 g) was used instead of propane-1,3-diol to obtain the title compound (1.02 g).

[0317] MS (m / z): 378.3[M+H] + .

[0318] [Step 2] Preparation of 3-{5-[2-(azacycloheptan-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one 4-methylbenzene-1-sulfonate In a mixture of 2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl 4-methylbenzene-1-sulfonate (30 mg), N,N-dimethylformamide (0.5 mL), and diisopropylethylamine (0.041 mL), azircycloheptane (16 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (121 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to give the title compound (27 mg).

[0319] MS (m / z): 305.1[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.44 (br, 1H), 7.92 (br, 1H), 7.68 (d, 2H), 7.54 (d, 1H), 7.21 (d, 2H), 4.51 (t, 2H), 3.68 (t, 2H), 3.50-3.45 (m, 4H), 2.35 (s, 3H), 1.98-1.91 (m, 4H), 1.77-1.72 (m, 4H).

[0320] Example 53 3-{5-[2-(4-methoxypiperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4- Oxadiazon-5-one In a mixture of 2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} ethyl 4-methylbenzene-1-sulfonate (45 mg), diisopropylethylamine (0.062 mL), and N,N-dimethylformamide (0.5 mL), 4-methoxypiperidine (41 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (181 mg) was added dropwise to adjust the pH to neutral. Purification was performed by silica gel column chromatography to obtain the title compound (10 mg).

[0321] MS (m / z): 321.1[M+H] + .

[0322] Example 54 3-{5-[2-(3-methoxypiperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4- Oxadiazon-5-one In a mixture of 2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl 4-methylbenzene-1-sulfonate (50 mg), N,N-dimethylformamide (0.5 mL), and diisopropylethylamine (0.069 mL) obtained in step 1 of Example 52, 3-methoxypiperidine (31 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. Hydrochloric acid was added to the reaction mixture to adjust the pH to neutral. Purification was performed by silica gel column chromatography to obtain the title compound (6 mg).

[0323] MS (m / z): 321.1[M+H] + .

[0324] Example 55 3-[5-(2-{7-azaspiro[4.5]decane-7-yl}ethoxy)pyridin-2-yl]-4,5-dihydro- 1,2,4-Oxadiazol-5-one In a mixture of 2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl 4-methylbenzene-1-sulfonate (50 mg), diisopropylethylamine (0.069 mL), and N,N-dimethylformamide (0.2 mL), 7-azaspiro[4,5]decane (37 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (101 mg) was added dropwise to adjust the pH to neutral. Purification was performed by silica gel column chromatography to obtain the title compound (23 mg).

[0325] MS (m / z): 345.1[M+H] + .

[0326] Example 56 3-[5-(2-{9-oxa-2-azaspiro[5.5]undecane-2-yl}ethoxy)pyridin-2-yl]- 4,5-Dihydro-1,2,4-oxadiazol-5-one In a mixture of 2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl 4-methylbenzene-1-sulfonate (45 mg), diisopropylethylamine (0.062 mL), and N,N-dimethylformamide (0.5 mL), 9-oxa-2-azaspiro[5.5]undecane (56 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (181 mg) was added dropwise to adjust the pH to neutral. Purification was performed by silica gel column chromatography to obtain the title compound (12 mg).

[0327] MS (m / z): 361.2[M+H] + .

[0328] Example 57 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} tert-butyl ethyl piperazine-1-carboxylate In a mixture of 2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl 4-methylbenzene-1-sulfonate (200 mg), diisopropylethylamine (0.275 mL), and N,N-dimethylformamide (5.3 mL), tert-butyl piperazine-1-carboxylate (197 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. After cooling to room temperature, acetic acid (0.46 mL) was added dropwise to adjust the pH to neutral. Purification was performed by silica gel column chromatography to obtain the title compound (25 mg).

[0329] MS (m / z): 390.2 [MH] - .

[0330] Example 58 3-{5-[2-(piperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Ketodihydrochloride In a mixture of 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid tert-butyl ester (19 mg) and tetrahydrofuran (0.5 mL), 0.24 mL of 4 M dioxane hydrochloride solution was added, and the mixture was stirred overnight. After concentration, 1.15 mL of 4 M hydrochloric acid was added dropwise to the reaction mixture, and the mixture was stirred overnight. 0.15 mL of 12 M hydrochloric acid was added dropwise to the reaction mixture, and the mixture was stirred for 8 hours. The reaction mixture was concentrated, and the resulting residue was washed with diethyl ether and dried to give the title compound (4 mg).

[0331] MS (m / z): 292.1[M+H] + 1H-NMR (400MHz, MeOH-d4) δ: 8.52 (d, 1H), 8.01 (d, 1H), 7.64 (dd, 1H), 4.62 (t, 2H), 3.86-3.60 (m, 10H).

[0332] Example 59 3-{5-[2-hydroxy-3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4- Oxadiazole-5-one hydrochloride [Step 1] Preparation of 5-[2-hydroxy-3-(piperidin-1-yl)propoxy]pyridine-2-carboxynitrile In a mixture of 5-hydroxypyridine-2-carboxynitrile (100 mg), 2-(chloromethyl)ethylene oxide (154 mg), and acetonitrile (1.5 mL), potassium carbonate (345 mg) was added sequentially at room temperature, and the mixture was heated and stirred at 70 °C for 5 hours. The insoluble matter was filtered off and concentrated. Water (1 mL) and piperidine (212 mg) were added, and the mixture was stirred at room temperature for 3 hours. Purification was performed by silica gel column chromatography to obtain the title compound (90 mg).

[0333] MS (m / z): 262.3[M+H] + .

[0334] [Step 2] Preparation of 3-{5-[2-hydroxy-3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 7, the title compound (25 mg) was obtained by using 5-[2-hydroxy-3-(piperidin-1-yl)propoxy]pyridine-2-carboxylonitrile (74 mg) instead of 5-[3-(piperidin-1-yl)propoxy]pyridine-2-carboxylonitrile (74 mg) obtained in step 1 of Example 59.

[0335] MS (m / z): 321.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.35 (d, 1H), 7.83 (d, 1H), 7.52 (dd, 1H), 4.16-3.97 (m, 3H), 2.60-2.40 (m, 6H), 1.70-1.35 (m, 6H).

[0336] Example 60 3-{5-[3-(4-hydroxypiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa Diazole-5-one hydrochloride [Step 1] Preparation of 5-(3-hydroxypropoxy)pyridine-2-carboxynitrile In a mixture of propane-1,3-diol (5.6 g) and N,N-dimethylformamide (5 mL), sodium hydride (60%, dispersed in liquid paraffin, 983 mg) was added, and the mixture was stirred at room temperature for 15 minutes. Then, 5-fluoropyridine-2-carboxynitrile (3 g) was added, and the mixture was stirred overnight. Water was added to the reaction mixture under ice cooling, and the mixture was purified by silica gel column chromatography to give the title compound (1.8 g).

[0337] MS (m / z): 179.2[M+H] + .

[0338] [Step 2] Preparation of 3-[(6-cyanopyridin-3-yl)oxy]propyl 4-methylbenzene-1-sulfonate In a mixture of 400 mg of 5-(3-hydroxypropoxy)pyridine-2-carboxynitrile and 1 mL of pyridine, 642 mg of 4-methylbenzene-1-sulfonyl chloride was added, and the mixture was stirred at room temperature for 1 hour. Hexane was added to the reaction solution, the precipitate was filtered off, and dried to give the title compound (690 mg).

[0339] MS (m / z): 333.2[M+H] + .

[0340] [Step 3] Preparation of 5-[3-(4-hydroxypiperidin-1-yl)propoxy]pyridine-2-carboxynitrile In a mixture of 3-[(6-cyanopyridin-3-yl)oxy]propyl 4-methylbenzene-1-sulfonate (186 mg), N,N-dimethylformamide (0.5 mL), and diisopropylethylamine (0.291 mL), piperidine-4-ol (170 mg) was added, and the mixture was heated and stirred at 80 °C for 2 hours. Purification was performed by silica gel column chromatography to obtain the title compound (98 mg).

[0341] MS (m / z): 262.3 (M+H) + .

[0342] [Step 4] Preparation of 3-{5-[3-(4-hydroxypiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride By following steps 2 and 3 of Example 7, the title compound (25 mg) was obtained by using 5-[3-(4-hydroxypiperidin-1-yl)propoxy]pyridine-2-carboxylonitrile (98 mg) instead of 5-[3-(piperidin-1-yl)propoxy]pyridine-2-carboxylonitrile (98 mg) obtained in step 3 of Example 60.

[0343] MS (m / z): 321.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.34 (d, 1H), 7.84 (d, 1H), 7.50 (dd, 1H), 4.69 (br, 1H), 4.17 (t, 2H), 3.60-3.45 (m, 1H), 2.98-2.86 (m, 2H), 2.72-2.62 (m, 2H), 2.35-2.45 (m, 2H), 2.20-1.85 (m, 2H), 1.84-1.54 (m, 2H), 1.54-1.50 (m, 2H).

[0344] Example 61 3-{5-[3-(3-hydroxypiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa Diazole-5-one hydrochloride By using piperidine-3-ol (170 mg) instead of piperidine-4-ol according to the method of Example 60, the title compound (15 mg) was obtained.

[0345] MS (m / z): 321.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 9.59 (br, 1H), 8.38 (d, 1H), 7.88 (d, 1H), 7.55 (dd, 1H), 4.76 (br, 1H), 4.17 (t, 2H), 3 .60-3.40 (m, 2H), 2.95-2.88 (m, 1H), 2.80-2.72 (m, 1H), 2.70-2.55 (m, 2H) 2.00-1.88 (m, 2H), 1.80-1.38 (m, 4H).

[0346] Example 62 3-{5-[3-(morpholin-4-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto Hydrochloride The title compound (35 mg) was obtained by using morpholine (380 mg) instead of piperidine-4-ol according to the method of Example 60.

[0347] MS (m / z): 307.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.42 (d, 1H), 7.92 (d, 1H), 7.59 (dd, 1H), 4.19 (t, 2H), 3.62-3.56 (m, 4H), 2.47 (t, 2H), 2.43-2.36 (m, 4H), 1.93 (dt, 2H) Elemental analysis values ​​(in C) 14 H 18 (N4O4・HCl) Calculated values ​​(%): C: 49.06, H: 5.59, N: 16.35 Measured values ​​(%) C: 49.38, H: 5.76, N: 16.55.

[0348] Example 63 3-{5-[3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1, 2,4-Oxadiazole-5-one hydrochloride The title compound (55 mg) was obtained by using 1,2,3,6-tetrahydropyridine (140 mg) instead of piperidine-4-ol according to the method of Example 60.

[0349] MS (m / z): 303.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.39 (d, 1H), 7.88 (d, 1H), 7.56 (dd, 1H), 5.77-5.64 (m, 2H), 4 .19 (t, 2H), 3.07-3.02 (m, 2H), 2.69-2.58 (m, 4H), 2.16-2.09 (m, 2H), 2.03-1.93 (m, 2H).

[0350] Example 64 3-[5-(3-{1,4-dioxa-8-azaspiro[4.5]decane-8-yl}propoxy)pyridine-2- ]-4,5-dihydro-1,2,4-oxadiazole-5-one hydrochloride The title compound (13 mg) was obtained by using 1,4-dioxa-8-azaspiro[4.5]decane (600 mg) instead of piperidine-4-ol, according to the method of Example 60.

[0351] MS (m / z): 363.3[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.33 (br, 1H), 7.85 (br, 1H), 7.45 (br, 1H), 4.25-4.14 ( m, 2H), 4.00-3.94 (m, 4H), 3.25-2.85 (m, 6H), 2.30-2.08 (m, 2H), 1.90-1.80 (m, 4H).

[0352] Example 65 1-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} propyl)piperidin-4-one 4-methylbenzene-1-sulfonate In a mixture of 3-[5-(3-{1,4-dioxa-8-azaspiro[4.5]decane-8-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride (100 mg) and water (5 mL), 4-methylbenzene-1-sulfonic acid hydrate (95 mg) was added, and the mixture was stirred overnight at room temperature. The concentrated residue was purified by silica gel column chromatography to give the title compound (70 mg).

[0353] MS (m / z): 319.0[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.39 (br, 1H), 7.93 (d, 1H), 7.69 (d, 2H), 7.51 (d, 1H), 7.23 (d, 2H), 4.9 5-4.85 (m, 2H), 4.24 (t, 2H), 3.44-3.20 (m, 6H), 2.36 (s, 3H), 2.34-2.22 (m, 2H), 2.10-1.92 (m, 2H).

[0354] Example 66 3-{5-[3-(3-fluoropiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-Azolium In the mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (100 mg), potassium carbonate (177 mg), and N,N-dimethylformamide (1 mL) obtained in step 3 of Example 51, 3-fluoropiperidine hydrochloride (107 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (243 mg) was added dropwise to the reaction mixture to adjust the pH to neutral. Purification was performed by silica gel column chromatography to obtain the title compound (29 mg).

[0355] MS (m / z): 323.0[M+H] + .

[0356] Example 67 3-{5-[3-(4-methylpiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa Diazole-5-one hydrochloride In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (80 mg), N,N-dimethylformamide (1 mL), and sodium iodide (92 mg) obtained in step 3 of Example 51, 4-methylpiperidine (61 mg) was added, and the mixture was heated and stirred overnight at 80 °C. The reaction mixture was adjusted to acidity by adding 2 M hydrochloric acid dropwise. Purification was performed by silica gel column chromatography to obtain the title compound (12 mg).

[0357] MS (m / z): 319.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.34 (d, 1H), 7.84 (d, 1H), 7.51 (dd, 2H), 7.19-7.02 (m, 3H), 4.16 (t, 2H), 3.03 (d, 2H) ), 2.66 (t, 2H), 2.21 (t, 2H), 2.02-1.92 (m, 2H), 1.64 (d, 2H), 1.48-1.34 (m, 1H), 1.27-1.13 (m, 2H), 0.89 (d, 3H).

[0358] Example 68 3-{5-[3-(4-methoxypiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4- Oxadiazole-5-one hydrochloride In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (80 mg), N,N-dimethylformamide (1 mL), and sodium iodide (92 mg) obtained in step 3 of Example 51, 4-methoxypiperidine (71 mg) was added, and the mixture was heated and stirred overnight at 80 °C. The reaction mixture was adjusted to acidity by adding 2 M hydrochloric acid dropwise. Purification was performed by silica gel column chromatography to obtain the title compound (12 mg).

[0359] MS (m / z): 335.0[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.35 (d, 1H), 7.85 (d, 1H), 7.52 (dd, 1H), 4.16 (t, 2H), 3.22 (s , 3H), 2.85-2.75 (m, 2H), 2.58 (t, 2H), 2.29 (t, 2H), 1.98-1.80 (m, 5H), 1.54-1.44 (m, 2H).

[0360] Example 69 3-(5-{3-[(trans)3,4-dihydroxypiperidin-1-yl]propoxy}pyridin-2-yl)-4,5-di Hydrogen-1,2,4-oxadiazole-5-one hydrochloride In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (15 mg), sodium iodide (11 mg), and N,N-dimethylformamide (0.3 mL) obtained in step 3 of Example 51, trans-piperidine-3,4-diol (9 mg) was added, and the mixture was heated and stirred at 100 °C for 1 hour. Hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (10 mg).

[0361] MS (m / z): 337.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.34 (br, 1H), 7.85 (d, 1H), 7.52 (dd, 1H), 4.85-4.65 (m, 2H), 4.15 (t, 2H), 2.50-2.40 (m, 1H), 2.90-2.75 (m, 2H), 2.08-1.70 (m, 6H), 1.44-1.32 (m, 1H).

[0362] Example 70 3-{5-[3-(4,4-difluoropiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4- Oxadiazole-5-one hydrochloride In the mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (80 mg) and N,N-dimethylformamide (1 mL) obtained in step 3 of Example 51, 4,4-difluoropiperidine (74 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. Hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (25 mg).

[0363] MS (m / z): 341.0[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.32 (d, 1H), 7.82 (d, 1H), 7.49 (dd, 1H), 4.14 (t, 2H), 2.50-2.42 (m, 6H), 2.00-1.84 (m, 6H).

[0364] Example 71 3-{5-[3-(4-fluoro-4-methylpiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1, 2,4-Oxadiazol-5-one 4-methylbenzene-1-sulfonate In the mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (47 mg), N,N-dimethylformamide (1 mL), and potassium carbonate (50 mg) obtained in step 3 of Example 51, 4-fluoro-4-methylpiperidine hydrochloride (56 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (180 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (14 mg).

[0365] MS (m / z): 337.3[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.44 (s, 1H), 7.97 (d, 1H), 7.62 (d, 1H), 7.47 (d, 2H), 7.11 (d, 2H), 4.24 (t, 2H), 3.25-2.94 (m, 6H), 2.29 (s, 3H), 2.20-1.75 (m, 6H), 1.40 (d, 3H).

[0366] Example 72 3-{5-[3-(4-acetylpiperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4- Oxadiazole-5-one 4-methylbenzene-1-sulfonate In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (50 mg), N,N-dimethylformamide (1.3 mL), and diisopropylethylamine (0.066 mL), 1-(piperazin-1-yl)ethane-1-one (33 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. At room temperature, an aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (194 mg) was added dropwise to adjust the pH to acidity. The solution was purified by silica gel column chromatography to give the title compound (9 mg).

[0367] MS (m / z): 348.1[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.40 (d, 1H), 7.97 (d, 1H), 7.70 (d, 2H), 7.53 (dd, 1H), 7.23 (d, 2H), 4 .27 (t, 2H), 4.00-3.65 (m, 2H), 3.42-3.18 (m, 8H), 2.36 (s, 3H), 2.34-2.23 (m, 2H), 2.15 (s, 3H).

[0368] Example 73 4-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} Methyl propyl piperazine-1-carboxylate [Step 1] Preparation of tert-butyl piperazine-1-carboxylate In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (50 mg), N,N-dimethylformamide (1.3 mL), and diisopropylethylamine (0.066 mL), tert-butyl piperazine-1-carboxylate (48 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. The reaction mixture was adjusted to acidity by adding 2 M hydrochloric acid dropwise at room temperature. Purification was performed by silica gel column chromatography to obtain the title compound (10 mg).

[0369] MS (m / z): 406.2[M+H] + .

[0370] [Step 2] Preparation of 3-{5-[3-(piperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one dihydrochloride In a mixture of 10 mg of tert-butyl piperazine-1-carboxylate and 1 mL of tetrahydrofuran, 0.031 mL of 4 M dioxane hydrochloride solution was added at room temperature and stirred for 15 hours. Then, 0.031 mL of 4 M dioxane hydrochloride solution and 0.5 mL of methanol were added, and the mixture was heated and stirred at 50 °C for 3 hours. Finally, 0.031 mL of 4 M dioxane hydrochloride solution was added, and the mixture was heated and stirred at 50 °C for 2 hours. The solvent was removed by vacuum distillation, the precipitate was washed with diethyl ether, and dried to give the title compound (10 mg).

[0371] MS (m / z): 306.1[M+H] + [Step 3] Preparation of methyl piperazine-1-carboxylate {[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl)piperazine-1-carboxylate In a mixture of 3-{5-[3-(piperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one dihydrochloride (9 mg), N,N-dimethylformamide (0.48 mL), and diisopropylethylamine (0.02 mL), methyl chloroformate (0.0018 mL) was added sequentially at room temperature, and the mixture was stirred for 1 hour. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (36 mg) was added dropwise to adjust the pH to acidic. Purification by silica gel column chromatography yielded the title compound (3 mg).

[0372] MS (m / z): 364.3[M+H] + .

[0373] Example 74 3-{5-[3-(piperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto-4-methylbenzene-1-sulfonate In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (300 mg), N,N-dimethylformamide (7.7 mL), and diisopropylethylamine (0.40 mL), tert-butyl piperazine-1-carboxylate (286 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. Acetic acid (0.66 mL) was added dropwise to the reaction mixture to adjust the pH to neutral. The crude product was obtained by purification by silica gel column chromatography.

[0374] The crude product was dissolved in tetrahydrofuran (0.94 mL), and 4 M dioxane hydrochloride solution (0.59 mL) was added. The mixture was stirred overnight at room temperature. The residue obtained by concentrating the reaction solution was washed with diethyl ether. Purification was performed by silica gel column chromatography to obtain the title compound (29 mg).

[0375] MS (m / z): 306.2[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.38 (d, 1H), 7.95 (d, 1H), 7.70 (d, 2H), 7.51 (dd, 1H), 7.23 (d , 2H), 4.22 (t, 2H), 3.25-3.18 (m, 4H), 2.85-2.60 (m, 6H), 2.36 (s, 3H), 2.10-2.00 (m, 2H).

[0376] Example 75 3-{5-[3-(4-benzylpiperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa Diazol-5-one 4-methylbenzene-1-sulfonate In a mixture of 3-{5-[3-(piperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one 4-methylbenzene-1-sulfonate (24 mg), N,N-dimethylformamide (0.25 mL), water (0.25 mL), and diisopropylethylamine (0.043 mL), bromomethylbenzene (9 mg) was added, and the mixture was stirred at room temperature for 3 hours. Purification was performed by silica gel column chromatography. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (1.6 mg) was added, and the mixture was concentrated to give the title compound (9 mg).

[0377] MS (m / z): 396.2[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.37 (d, 1H), 7.93 (d, 1H), 7.69 (d, 2H), 7.49 (dd, 1H), 7.45-7.32 (m, 5H), 7.21 (d, 2H), 4.22 (t, 2H), 3.86 (s, 2H), 3.25-2.75 (m, 10H), 2.35 (s, 3H), 2.23-2.14 (m, 2H).

[0378] Example 76 3-[5-(3-{3-azabicyclo[3.1.0]hexane-3-yl}propoxy)pyridin-2-yl]-4,5-di Hydrogen-1,2,4-oxadiazole-5-one hydrochloride In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (80 mg), N,N-dimethylformamide (1 mL), and diisopropylethylamine (0.177 mL), 3-azabicyclo[3.1.0]hexane hydrochloride (73 mg) was added, and the mixture was heated and stirred at 80 °C for 5 hours. The reaction mixture was adjusted to acidity by adding 2 M hydrochloric acid dropwise. Purification was performed by silica gel column chromatography to obtain the title compound (30 mg).

[0379] MS (m / z): 303.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.37 (d, 1H), 7.88 (d, 1H), 7.54 (dd, 1H), 4.15 (t, 2H), 3.05 (d, 2H), 2.67 (t, 2H), 2.52-2.38 (m, 2H), 1.90 (dt, 2H), 1.42-1.36 (m, 2H), 0.60-0.55 (m, 1H), 0.39-0.32 (m, 1H).

[0380] Example 77 3-[5-(3-{octahydrocyclopentanol[c]pyrrolo-2-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1, 2,4-Oxadiazole-5-one hydrochloride In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (80 mg), N,N-dimethylformamide (1 mL), and sodium iodide (92 mg) obtained in step 3 of Example 51, octahydrocyclopenta[c]pyrrole (68 mg) was added, and the mixture was heated and stirred overnight at 80 °C. The reaction mixture was adjusted to acidity by adding 2 M hydrochloric acid dropwise. Purification was performed by silica gel column chromatography to obtain the title compound (12 mg).

[0381] MS (m / z): 331.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.30 (d, 1H), 7.80 (d, 1H), 7.45 (dd, 1H), 4.16 (t, 2H), 3.0-2.86 (m, 2H ), 2.78-2.67 (m, 2H), 2.64-2.54 (m, 2H), 2.40-2.30 (m, 2H), 1.98-1.92 (m, 2H), 1.65-1.34 (m, 6H).

[0382] Example 78 3-[5-(3-{7-azaspiro[4.5]decane-7-yl}propoxy)pyridin-2-yl]-4,5-dihydro- 1,2,4-Oxadiazol-5-one 4-methylbenzene-1-sulfonate In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (100 mg), N,N-dimethylformamide (0.2 mL), and diisopropylethylamine (0.13 mL), 7-azaspiro[4,5]decane (53 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (243 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (35 mg).

[0383] MS (m / z): 359.2[M+H] + 1H-NMR (400MHz, MeOH-d4) δ: 8.34 (d, 1H), 7.86 (d, 1H), 7.69 (d, 2H), 7.44 (dd, 1H), 7.22 (d, 2H), 4.21 (t, 2H), 3.50-2.29 (m, 6H), 2.35 (s, 3H), 2.35-2.24 (m, 2H), 1.94-1.84 (m, 2H), 1.75-1.45 (m, 10H).

[0384] Example 79 3-[5-(3-{2-oxa-8-azaspiro[4.5]decane-8-yl}propoxy)pyridin-2-yl]-4, 5-Dihydro-1,2,4-Oxadiazol-5-one 4-methylbenzene-1-sulfonate In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (80 mg), sodium iodide (92 mg), diisopropylethylamine (0.11 mL), and N,N-dimethylformamide (0.5 mL), 2-oxa-8-azaspiro[4.5]decane (87 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (194 mg) was added to the reaction mixture to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (8 mg).

[0385] MS (m / z): 361.3[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.35 (d, 1H), 7.86 (d, 1H), 7.68 (dd, 2H), 7.44 (dd, 1H), 7.22 (d, 2H), 4.22 (t , 2H), 3.88 (t, 2H), 3.59 (s, 2H), 3.38-3.25 (m, 6H), 2.35 (s, 3H), 2.35-2.25 (m, 2H), 1.92-1.82 (m, 6H).

[0386] Example 80 3-[5-(3-{9-oxa-2-azaspiro[5.5]undecane-2-yl}propoxy)pyridin-2-yl]- 4,5-Dihydro-1,2,4-oxadiazol-5-one 4-methylbenzene-1-sulfonate In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (47 mg), N,N-dimethylformamide (1 mL), and diisopropylethylamine (0.062 mL), 9-oxa-2-azaspiro[5.5]undecane (56 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (180 mg) was added dropwise to adjust the pH to acidity. Purification was performed by silica gel column chromatography to obtain the title compound (22 mg).

[0387] MS (m / z): 375.4[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.43 (s, 1H), 7.95 (d, 1H), 7.60 (dd, 1H), 7.49 (d, 2H), 7.09 (d, 2H), 4.25 (t, 2H), 3.35-3.15 (m, 2H), 3.65-3.48 (m, 6H), 2.28 (s, 3H), 2.25-2.13 (m, 2H), 1.82-1.30 (m, 10H).

[0388] Example 81 1-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} propylpyridine-1-onium 4-methylbenzene-1-sulfonate In a mixture of 3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl 4-methylbenzene-1-sulfonate (170 mg), sodium iodide (130 mg), and N,N-dimethylformamide (0.3 mL) obtained in step 3 of Example 51, pyridine (0.3 mL) was added, and the mixture was heated and stirred at 100 °C for 1 hour. Hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (40 mg).

[0389] MS (m / z): 299.2 [M] + 1 H-NMR (400MHz, DMSO-d6) δ: 9.15 (d, 2H), 8.63 (t, 1H), 8.17 (t, 2H), 8.06 (d, 1H), 7.74 (d, 1H), 7. 48 (d, 2H), 7.32 (d, 1H), 7.11 (d, 2H), 4.82 (t, 2H), 4.21 (t, 2H), 2.48-2.42 (m, 2H), 2.29 (s, 3H).

[0390] Example 82 3-{5-[(5-methyl-1,3-oxazol-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2, 4-Oxadiazol-5-one To the mixture of 3-(5-fluoropyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (50 mg), (5-methyl-1,3-oxazol-4-yl)methanol (62 mg), and 1-methylpyrrolidone-2-one (0.9 mL) obtained in step 1 of Example 51, KO was added. t Bu (62 mg) was heated and stirred at 60 °C for 2 hours, and then heated and stirred at 80 °C for 15 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (420 mg) was added dropwise to the reaction solution at room temperature to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (2 mg).

[0391] MS (m / z): 275.1[M+H] + .

[0392] Example 83 3-{5-[(1,3-thiazolyl-2-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-Azolium In the mixture of 3-(5-fluoropyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (50 mg), (1,3-thiazolyl)methanol (79 mg), and 1-methylpyrrolidone-2-one (0.9 mL) obtained in step 1 of Example 51, KO was added. t Bu (77 mg) was heated and stirred at 60 °C for 15 hours. At room temperature, an aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (420 mg) was added dropwise to adjust the pH to acidity. Purification was performed by silica gel column chromatography to obtain the title compound (6 mg).

[0393] MS (m / z): 277.0[M+H] + .

[0394] Example 84 3-{5-[3-(pyridin-3-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Ketone The title compound (7 mg) was obtained by using 3-(pyridin-3-yl)propane-1-ol (57 mg) instead of (1,3-thiazolyl-2-yl)methanol according to the method of Example 83.

[0395] MS (m / z): 299.0[M+H] + .

[0396] Example 85 1-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} (propyl)piperidin-2-one In the mixture of 3-(5-fluoropyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (50 mg), 1-(3-hydroxypropyl)piperidin-2-one (87 mg), and 1-methylpyrrolidone-2-one (0.1 mL) obtained in step 1 of Example 51, KO was added. t Bu (62 mg) was heated and stirred at 60 °C for 3 hours. Hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (45 mg).

[0397] MS (m / z): 319.1[M+H] + .

[0398] Example 86 3-{5-[2-methyl-3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4- Oxadiazole-5-one 4-methylbenzene-1-sulfonate The title compound (83 mg) was obtained by using 2-methyl-3-(piperidin-1-yl)propane-1-ol (87 mg) instead of (1,3-thiazolyl-2-yl)methanol according to the method of Example 83.

[0399] MS (m / z): 319.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.44 (d, 1H), 7.98 (d, 1H), 7.61 (dd, 1H), 7.47 (d, 2H), 7.11 (d, 2H), 4.14-4.06 (m , 2H), 3.50-3.26 (m, 2H), 3.24-3.16 (m, 2H), 3.08-3.00 (m, 2H), 2.29 (s, 3H), 1.95-1.22 (m, 7H), 1.11 (d, 3H).

[0400] Example 87 3-{5-[2-(dimethylamino)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto-4-methylbenzene-1-sulfonate The title compound (63 mg) was obtained by using 2-(dimethylamino)ethane-1-ol (37 mg) instead of (1,3-thiazolyl-2-yl)methanol according to the method of Example 83.

[0401] MS (m / z): 251.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.48 (d, 1H), 8.00 (d, 1H), 7.67 (dd, 1H), 7.47 (d, 2H), 7.11 (d, 2H), 4.51 (t, 2H), 3.55 (t, 2H), 2.87 (s, 6H), 2.29 (s, 3H).

[0402] Example 88 3-{5-[3-(dimethylamino)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto-4-methylbenzene-1-sulfonate The title compound (64 mg) was obtained by using 3-(dimethylamino)propane-1-ol (43 mg) instead of (1,3-thiazolyl-2-yl)methanol according to the method of Example 83.

[0403] MS (m / z): 265.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.44 (d, 1H), 7.97 (d, 1H), 7.61 (dd, 1H), 7.47 (d, 2H), 7 .11 (d, 2H), 4.24 (t, 2H), 3.23 (t, 2H), 2.82 (s, 6H), 2.29 (s, 3H), 2.18-2.10 (m, 2H).

[0404] Example 89 3-{5-[4-(dimethylamino)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto-4-methylbenzene-1-sulfonate The title compound (53 mg) was obtained by using 4-(dimethylamino)butane-1-ol (49 mg) instead of (1,3-thiazolyl-2-yl)methanol according to the method of Example 83.

[0405] MS (m / z): 279.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 9.21 (br, 1H), 8.44 (d, 1H), 7.96 (d, 1H), 7.61 (dd, 1H), 7.47 (d, 2H ), 7.11 (d, 2H), 4.19 (t, 2H), 3.17-3.18 (m, 2H), 2.79 (s, 6H), 2.29 (s, 3H), 1.83-1.73 (m, 4H).

[0406] Example 90 3-{5-[4-(piperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto Hydrochloride By following steps 1, 2 and 3 of Example 7, 4-(piperidin-1-yl)butane-1-ol (232 mg) was used instead of 3-(piperidin-1-yl)propane-1-ol to obtain the title compound (112 mg).

[0407] MS (m / z): 319.1[M+H] + 1H-NMR (400MHz, DMSO-d6) δ: 8.31 (d, 1H), 7.79 (d, 1H), 7.40 (dd, 1H), 4.09 (br, 2H), 2.90-2.65 (m, 6H), 1.85-1.34 (m, 10H).

[0408] Example 91 3-{5-[4-(azacycloheptan-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa Diazol-5-one 4-methylbenzene-1-sulfonate [Step 1] Preparation of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}butyl 4-methylbenzene-1-sulfonate By following steps 1, 2 and 3 of Example 51, butane-1,4-diol (12 g) was used instead of propane-1,3-diol to obtain the title compound (4.89 g).

[0409] MS (m / z): 406.1[M+H] + .

[0410] [Step 2] Preparation of 3-{5-[4-(azacycloheptan-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one 4-methylbenzene-1-sulfonate A mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (30 mg), N,N-dimethylformamide (0.5 mL), and diisopropylethylamine (0.038 mL) was added to azacycloheptanane (22 mg), and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonate hydrate (113 mg) was added dropwise to adjust the pH to acidity. Purification was performed by silica gel column chromatography to obtain the title compound (26 mg).

[0411] MS (m / z): 333.2[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.43 (d, 1H), 7.95 (d, 1H), 7.61 (dd, 1H), 7.47 (d, 2H), 7.11 (d, 2H) ), 4.22-4.16 (m, 2H), 3.30-3.12 (m, 6H), 2.29 (s, 3H), 1.85-1.72 (m, 8H), 1.66-1.56 (m, 4H).

[0412] Example 92 3-{5-[4-(pyrrolidone-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-oxazolone 4-methylbenzene-1-sulfonate In the mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (50 mg) and N,N-dimethylformamide (0.5 mL) obtained in step 1 of Example 91, pyrrolidine (26 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (164 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (35 mg).

[0413] MS (m / z): 305.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.36 (br, 1H), 7.86 (d, 1H), 7.50-7.42 (m, 3H), 7. 12 (d, 2H), 4.11 (br, 2H), 3.30-3.05 (m, 6H), 2.29 (s, 3H), 1.98-1.72 (m, 8H).

[0414] Example 93 3-{5-[4-(3-hydroxypiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxa Diazol-5-one 4-methylbenzene-1-sulfonate In a mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (49 mg), N,N-dimethylformamide (1 mL), and diisopropylethylamine (0.062 mL), piperidin-3-ol (37 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (180 mg) was added to the reaction mixture to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (1 mg).

[0415] MS (m / z): 335.1[M+H] + .

[0416] Example 94 3-{5-[4-(morpholin-4-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Keto-4-methylbenzene-1-sulfonate In the mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (49 mg), N,N-dimethylformamide (1 mL), and diisopropylethylamine (0.062 mL), morpholine (37 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (180 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (25 mg).

[0417] MS (m / z): 321.1[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.38 (d, 1H), 7.95 (d, 1H), 7.70 (d, 2H), 7.51 (dd, 1H), 7.22 (d , 2H), 4.19 (t, 2H), 3.95-3.82 (m, 4H), 3.35-3.17 (m, 6H), 2.36 (s, 3H), 2.00-1.86 (m, 4H).

[0418] Example 95 3-{5-[4-(4-fluoropiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-oxazolone 4-methylbenzene-1-sulfonate In the mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (49 mg), N,N-dimethylformamide (0.5 mL), and potassium carbonate (50 mg) obtained in step 1 of Example 91, 4-fluoropiperidine hydrochloride (51 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (184 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (23 mg).

[0419] MS (m / z): 337.2[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.38 (d, 1H), 7.96 (d, 1H), 7.70 (d, 2H), 7.52 (dd, 1H ), 7.23 (d, 2H), 4.21 (t, 2H), 3.50-3.16 (m, 7H), 2.36 (s, 3H), 2.30-1.86 (m, 8H).

[0420] Example 96 3-{5-[4-(4,4-dimethylpiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2, 4-Oxadiazol-5-one 4-methylbenzene-1-sulfonate In the mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (49 mg), N,N-dimethylformamide (0.5 mL), and potassium carbonate (50 mg) obtained in step 1 of Example 91, 4,4-dimethylpiperidine hydrochloride (54 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonate hydrate (184 mg) was added dropwise to adjust the pH to acidity. Purification was performed by silica gel column chromatography to obtain the title compound (16 mg).

[0421] MS (m / z): 347.2[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.36 (d, 1H), 7.93 (d, 1H), 7.70 (d, 2H), 7.49 (dd, 1H), 7.22 (d, 2H), 4.18 (t, 2H) ), 3.54-3.00 (m, 6H), 3.40-2.90 (m, 6H), 2.36 (s, 3H), 2.04-1.85 (m, 4H), 1.74-1.58 (m, 4H), 1.06 (s.6H).

[0422] Example 97 3-{5-[4-(3-hydroxy-3-methylpiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro- 1,2,4-Oxadiazol-5-one In a mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (50 mg), N,N-dimethylformamide (0.5 mL), and diisopropylethylamine (0.064 mL), 3-methylpiperidin-3-ol (43 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. Hydrochloric acid was added to the reaction mixture to adjust the pH to neutral. Purification was performed by silica gel column chromatography to obtain the title compound (23 mg).

[0423] MS (m / z): 349.2[M+H] + .

[0424] Example 98 3-[5-(4-{7-azaspiro[4.5]decane-7-yl}butoxy)pyridin-2-yl]-4,5-dihydro- 1,2,4-Oxadiazol-5-one In a mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (50 mg), N,N-dimethylformamide (0.2 mL), and diisopropylethylamine (0.064 mL), 7-azaspiro[4,5]decane (34 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (94 mg) was added dropwise to adjust the pH to neutral. Purification was performed by silica gel column chromatography to obtain the title compound (23 mg).

[0425] MS (m / z): 373.2[M+H] + .

[0426] Example 99 3-[5-(4-{9-oxa-2-azaspiro[5.5]undecane-2-yl}butoxy)pyridin-2-yl]- 4,5-Dihydro-1,2,4-oxadiazol-5-one 4-methylbenzene-1-sulfonate In a mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (49 mg), N,N-dimethylformamide (0.5 mL), and diisopropylethylamine (0.063 mL), 9-oxa-2-azaspiro[5.5]undecane (56 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (184 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (5 mg).

[0427] MS (m / z): 389.2[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.36 (br, 1H), 7.91 (br, 1H), 7.70 (d, 2H), 7.46 (dd, 1H), 7.22 ( d, 2H), 4.16 (t, 2H), 3.78-3.59 (m, 4H), 3.40-2.90 (m, 6H) 2.36 (s, 3H), 2.50-1.45 (m, 12H).

[0428] Example 100 4-(4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} 4-Methylbenzene-1-sulfonate (butyl)piperazine-1-carboxylate [Step 1] Preparation of tert-butyl piperazine-1-carboxylate In Example 91, a mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (50 mg), dimethyl sulfoxide (1 mL), and diisopropylethylamine (0.064 mL) was added, and tert-butyl piperazine-1-carboxylate (46 mg) was heated and stirred at 80 °C for 3 hours. The reaction mixture was adjusted to acidity by adding 2 M hydrochloric acid dropwise at room temperature. Purification was performed by silica gel column chromatography to obtain the title compound (13 mg).

[0429] MS (m / z): 418.3 [MH] - .

[0430] [Step 2] Preparation of 3-{5-[4-(piperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one dihydrochloride In a mixture of 4-(4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}butyl)piperazine-1-carboxylic acid tert-butyl ester (13 mg) and tetrahydrofuran (1 mL), 0.039 mL of 4M dioxane hydrochloride solution was added at room temperature and the mixture was stirred for 15 hours. Then, 0.039 mL of 4M dioxane hydrochloride solution and 0.5 mL of methanol were added, and the mixture was heated and stirred at 50 °C for 3 hours. Finally, 0.039 mL of 4M dioxane hydrochloride solution was added, and the mixture was heated and stirred at 50 °C for 2 hours. The solvent was removed by vacuum distillation, and the precipitate was filtered through diethyl ether and dried to give the title compound (14 mg).

[0431] MS (m / z): 320.1[M+H] + .

[0432] [Step 3] Preparation of 4-(4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}butyl)piperazine-1-carboxylate 4-methylbenzene-1-sulfonate) In a mixture of 3-{5-[4-(piperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one dihydrochloride (11 mg), N,N-dimethylformamide (0.31 mL), and diisopropylethylamine (0.026 mL), methyl chloroformate (0.0024 mL) was added sequentially at room temperature, and the mixture was stirred for 1 hour. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (47 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to give the title compound (2 mg).

[0433] MS (m / z): 378.1[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.38 (d, 1H), 7.95 (d, 1H), 7.70 (d, 2H), 7.51 (dd, 1H), 7.23 (d , 2H), 4.19 (t, 2H), 3.78-3.70 (m, 5H), 3.35-3.23 (m, 8H), 2.36 (s, 3H), 2.02-1.89 (m, 4H).

[0434] Example 101 3-{5-[4-(4-acetylpiperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2, 4-Oxadiazol-5-one 4-methylbenzene-1-sulfonate In a mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (50 mg), N,N-dimethylformamide (1.2 mL), and diisopropylethylamine (0.064 mL), 1-(piperazin-1-yl)ethane-1-one (32 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. At room temperature, an aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (188 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to give the title compound (22 mg).

[0435] MS (m / z): 362.2[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.38 (d, 1H), 7.95 (d, 1H), 7.70 (d, 2H), 7.51 (dd, 1H), 7.23 (d, 2H), 4 .21 (t, 2H), 4.00-3.62 (m, 2H), 3.50-3.18 (m, 8H), 2.36 (s, 3H), 2.15 (s, 3H), 2.06-1.86 (m, 4H).

[0436] Example 102 3-{5-[4-(piperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazole- 5-Ketodihydrochloride In a mixture of 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy} butyl 4-methylbenzene-1-sulfonate (200 mg), N,N-dimethylformamide (4.9 mL), and diisopropylethylamine (0.26 mL), tert-butyl piperazine-1-carboxylate (184 mg) was added, and the mixture was heated and stirred at 80 °C for 3 hours. Acetic acid (0.42 mL) was added dropwise to adjust the pH to neutral. The crude product was purified by silica gel column chromatography. The crude product was dissolved in THF (0.46 mL), and 4 M dioxane hydrochloride solution (0.29 mL) was added. The mixture was stirred overnight at room temperature. The residue obtained by concentrating the reaction solution was washed with diethyl ether. The title compound (28 mg) was purified by silica gel column chromatography.

[0437] MS (m / z): 320.2[M+H] + 1 H-NMR (400MHz, MeOH-d4) δ: 8.36 (d, 1H), 7.94 (d, 1H), 7.50 (dd, 1H), 4.70-4.50 (m, 2H), 4.17 (t , 2H), 3.20-3.12 (m, 4H), 2.80-2.65 (m, 4H), 2.53 (t, 2H), 1.95-1.82 (m, 2H), 1.75-1.68 (m, 2H).

[0438] Example 103 3-{5-[4-(4-benzylpiperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4- Oxadiazon-5-one In a mixture of 3-{5-[4-(piperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one dihydrochloride (21 mg), N,N-dimethylformamide (0.27 mL), water (0.27 mL), and diisopropylethylamine (0.046 mL), bromomethylbenzene (10 mg) was added, and the mixture was stirred at room temperature for 3 hours. Purification was performed by silica gel column chromatography to obtain the title compound (4 mg).

[0439] MS (m / z): 410.3[M+H] + .

[0440] Example 104 3-(5-{[5-(piperidin-1-yl)pentyl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxa diazol-5-one To the mixture of 3-(5-fluoropyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (50 mg), 5-(piperidin-1-yl)pentan-1-ol (118 mg), and 1-methylpyrrolidone-2-one (0.3 mL) obtained in step 1 of Example 51, KO was added.t Bu (77 mg) was heated and stirred at 60 °C for 3 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (105 mg) was added dropwise to the reaction mixture to adjust the pH to neutral. Purification was performed by silica gel column chromatography to obtain the title compound (28 mg).

[0441] MS (m / z): 333.1[M+H] + .

[0442] Example 105 3-(5-{[2-(3-methoxyphenyl)ethyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4- Oxadiazon-5-one [Step 1] Preparation of 5-{[2-(3-methoxyphenyl)ethyl]amino}pyridine-2-carboxynitrile Potassium carbonate (85 mg) was added to a mixture of 5-fluoropyridine-2-carboxynitrile (50 mg), 2-(3-methoxyphenyl)ethane-1-amine (62 mg), and N,N-dimethylformamide (1.4 mL), and the mixture was heated and stirred at 80 °C for 15 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (89 mg).

[0443] MS (m / z): 254.1[M+H] + .

[0444] [Step 2] Preparation of N-hydroxy-5-{[2-(3-methoxyphenyl)ethyl]amino}pyridine-2-carboximide amide In a mixture of hydroxylamine hydrochloride (122 mg) and ethanol (1.8 mL), 0.88 mL of 2 M sodium hydroxide aqueous solution was added, and the mixture was stirred at room temperature for 10 minutes. 5-{[2-(3-methoxyphenyl)ethyl]amino}pyridine-2-carboxynitrile (89 mg) was added to the reaction mixture, and the mixture was stirred at room temperature for 15 hours. The reaction mixture was purified by silica gel column chromatography to obtain the title compound (82 mg).

[0445] MS (m / z): 287.1[M+H] + .

[0446] [Step 3] Preparation of 3-(5-{[2-(3-methoxyphenyl)ethyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one In a mixture of N-hydroxy-5-{[2-(3-methoxyphenyl)ethyl]amino}pyridine-2-carboximide amide (82 mg), tetrahydrofuran (1.4 mL), and DBU (0.064 mL), CDI (70 mg) was added at room temperature and the mixture was stirred for 15 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (436 mg) was added dropwise to adjust the pH to acidity. Purification was performed by silica gel column chromatography to obtain the title compound (81 mg).

[0447] MS (m / z): 313.0[M+H] + .

[0448] Example 106 3-(5-{[2-(3-fluorophenyl)ethyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazine 5-Azolium By following steps 1, 2 and 3 of Example 105, 2-(3-fluorophenyl)ethane-1-amine (57 mg) was used instead of 2-(3-methoxyphenyl)ethane-1-amine to obtain the title compound (82 mg).

[0449] MS (m / z): 301.0[M+H] + .

[0450] Example 107 3-(5-{[2-(pyridin-4-yl)ethyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxa diazol-5-one By following steps 1, 2 and 3 of Example 105, 2-(pyridin-4-yl)ethane-1-amine (50 mg) was used instead of 2-(3-methoxyphenyl)ethane-1-amine to obtain the title compound (10 mg).

[0451] MS (m / z): 284.1[M+H] + .

[0452] Example 108 3-(5-{[3-(piperidin-1-yl)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxa Diazol-5-one 4-methylbenzene-1-sulfonate [Step 1] Preparation of N-hydroxy-5-{[3-(piperidin-1-yl)propyl]amino}pyridine-2-carboximide amide By following steps 1 and 2 of Example 105, 3-(piperidin-1-yl)propane-1-amine (58 mg) was used instead of 2-(3-methoxyphenyl)ethane-1-amine to obtain the title compound (55 mg).

[0453] MS (m / z): 278.1[M+H] + .

[0454] [Step 2] Preparation of 3-(5-{[3-(piperidin-1-yl)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one 4-methylbenzene-1-sulfonate In a mixture of N-hydroxy-5-{[3-(piperidin-1-yl)propyl]amino}pyridine-2-carboximide amide (55 mg), tetrahydrofuran (0.99 mL), and DBU (0.044 mL), CDI (48 mg) was added at room temperature and the mixture was stirred for 15 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (302 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (40 mg).

[0455] MS (m / z): 304.1[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.07 (d, 1H), 7.70 (d, 1H), 7.47 (d, 2H), 7.13-7.06 (m, 3H), 6.81 (t, 1H), 3. 50-3.28 (m, 2H), 3.21 (dd, 2H), 3.13-3.07 (m, 2H), 3.00-2.70 (m, 2H), 2.29 (s, 3H), 1.94-1.18 (m, 8H).

[0456] Example 109 3-(5-{[(1-ethylpiperidin-4-yl)methyl]amino}pyridin-2-yl)-4,5-dihydro-1,2, 4-Oxadiazol-5-one [Step 1] Preparation of 5-{[(1-ethylpiperidin-4-yl)methyl]amino}pyridine-2-carboxylonitrile In a mixture of (1-ethylpiperidin-4-yl)methaneamine (140 mg), 5-fluoropyridine-2-carboxynitrile (100 mg), and dimethyl sulfoxide (1 mL), potassium carbonate (170 mg) was added sequentially at room temperature, and the mixture was heated and stirred at 120 °C for 3 hours. Water was added to the reaction solution, and the mixture was purified by silica gel column chromatography to obtain the title compound (205 mg).

[0457] MS (m / z): 245.3[M+H] + [Step 2] Preparation of 5-{[(1-ethylpiperidin-4-yl)methyl]amino}-N-hydroxypyridine-2-carboximide amide In a mixture of hydroxylamine hydrochloride (350 mg) and dimethyl sulfoxide (1 mL), KO was added sequentially at room temperature. t Bu (565 mg) was stirred for 10 minutes. 5-{[(1-ethylpiperidin-4-yl)methyl]amino}pyridine-2-carboxylonitrile (205 mg) was added, and the mixture was stirred overnight. Water was added to the reaction mixture, the precipitate was filtered off, and dried to give the title compound (152 mg).

[0458] MS (m / z): 278.3[M+H] + .

[0459] [Step 3] Preparation of 3-(5-{[(1-ethylpiperidin-4-yl)methyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one In a mixture of 5-{[(1-ethylpiperidin-4-yl)methyl]amino}-N-hydroxypyridine-2-carboximide amide (152 mg), tetrahydrofuran (1 mL), and DBU (0.098 mL), CDI (133 mg) was added at room temperature and stirred overnight. Water was added to the reaction mixture, and hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography. The fraction containing the target compound was neutralized with an aqueous solution of potassium carbonate and purified by silica gel column chromatography to give the title compound (112 mg).

[0460] MS (m / z): 304.2[M+H] + .

[0461] Example 110 3-(5-{methyl[3-(piperidin-1-yl)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2, 4-Oxadiazole-5-one hydrochloride [Step 1] Preparation of N-hydroxy-5-{methyl[3-(piperidin-1-yl)propyl]amino}pyridine-2-carboximide amide By following steps 1 and 2 of Example 105, methyl [3-(piperidin-1-yl)propyl]amine (77 mg) was used instead of 2-(3-methoxyphenyl)ethane-1-amine to obtain the title compound (99 mg).

[0462] MS (m / z): 259.4[M+H] + .

[0463] [Step 2] Preparation of 3-(5-{methyl[3-(piperidin-1-yl)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one hydrochloride In a mixture of N-hydroxy-5-{methyl[3-(piperidin-1-yl)propyl]amino}pyridine-2-carboximide amide (99 mg), tetrahydrofuran (3 mL), and DBU (0.076 mL), CDI (83 mg) was added at room temperature and stirred overnight. Water was added to the reaction mixture, and hydrochloric acid was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (80 mg).

[0464] MS (m / z): 318.4[M+H] + 1H-NMR (400MHz, DMSO-d6) δ: 8.10 (d, 1H), 7.67 (d, 1H), 7.18 (dd, 1H), 3.45 (t , 2H), 2.98 (s, 3H), 2.55-2.35 (m, 6H), 1.78-1.66 (m, 2H), 1.62-1.32 (m, 6H).

[0465] Example 111 3-(5-{[2-(dimethylamino)ethyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxa Diazol-5-one 4-methylbenzene-1-sulfonate [Step 1] Preparation of 5-{[2-(dimethylamino)ethyl]amino}pyridine-2-carboxynitrile A mixture of 5-fluoropyridine-2-carboxynitrile (50 mg), (2-aminoethyl)dimethylamine (40 mg), 1-methylpyrrolidone-2-one (2.0 mL), and potassium carbonate (85 mg) was heated and stirred at 80 °C for 3 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (66 mg).

[0466] MS (m / z): 191.3[M+H] + .

[0467] [Step 2] Preparation of 5-{[2-(dimethylamino)ethyl]amino}-N-hydroxypyridine-2-carboximide amide In a mixture of hydroxylamine hydrochloride (121 mg) and ethanol (1.7 mL), 0.87 mL of 2 M sodium hydroxide aqueous solution was added sequentially at room temperature and stirred for 10 minutes. Then, 66 mg of 5-{[2-(dimethylamino)ethyl]amino}pyridine-2-carboxynitrile was added and the mixture was stirred for 5 hours. The reaction solution was purified by silica gel column chromatography to obtain the title compound (83 mg).

[0468] MS (m / z): 224.3[M+H] + .

[0469] [Step 3] Preparation of 3-(5-{[2-(dimethylamino)ethyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one 4-methylbenzene-1-sulfonate In a mixture of 5-{[2-(dimethylamino)ethyl]amino}-N-hydroxypyridine-2-carboximide amide (83 mg), tetrahydrofuran (1.9 mL), and DBU (0.083 mL), CDI (90 mg) was added at room temperature and the mixture was stirred for 14 hours. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (566 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to give the title compound (97 mg).

[0470] MS (m / z): 250.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.11 (d, 1H), 7.73 (d, 1H), 7.48 (d, 2H), 7.16 (dd, 1H) , 7.12 (d, 2H), 6.84 (t, 1H), 3.53 (dt, 2H), 3.25 (t, 2H), 2.83 (s, 6H), 2.29 (s, 3H).

[0471] Example 112 3-(5-{[3-(dimethylamino)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxa Diazol-5-one 4-methylbenzene-1-sulfonate By following steps 1, 2 and 3 of Example 111, (3-aminopropyl)dimethylamine (46 mg) was used instead of (2-aminoethyl)dimethylamine to obtain the title compound (113 mg).

[0472] MS (m / z): 264.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 9.25 (br, 1H), 8.06 (d, 1H), 7.71 (d, 1H), 7.47 (d, 2H), 7.21-7.01 ( m, 3H), 6.80 (t, 1H), 3.25-3.17 (m, 2H), 3.13 (t, 2H), 2.79 (s, 6H), 2.29 (s, 3H), 1.90 (tt, 2H).

[0473] Example 113 3-(5-{[4-(dimethylamino)butyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxa Diazol-5-one 4-methylbenzene-1-sulfonate By following steps 1, 2 and 3 of Example 111, (4-aminobutyl)dimethylamine (52 mg) was used instead of (2-aminoethyl)dimethylamine to obtain the title compound (148 mg).

[0474] MS (m / z): 278.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 9.22 (br, 1H), 8.06 (d, 1H), 7.69 (d, 1H), 7.47 (d, 2H), 7.11 (d, 1H), 7.05 (dd, 1H), 6.78 (t, 1H), 3.20-3.13 (m, 2H), 3.07 (t, 2H), 2.77 (s, 6H), 2.29 (s, 3H), 1.74-1.65 (m, 2H), 1.61-1.53 ​​(m, 2H).

[0475] Example 114 3-{5-[(1-ethylpiperidin-4-yl)amino]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-oxazolone 4-methylbenzene-1-sulfonate By following steps 1, 2 and 3 of Example 111, 1-ethylpiperidine-4-amine (58 mg) was used instead of (2-aminoethyl)dimethylamine to obtain the title compound (79 mg).

[0476] MS (m / z): 290.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.11 (br, 1H), 7.70 (d, 1H), 7.48 (d, 2H), 7.20-7.02 (m, 3H), 6.83 (d, 1H), 3.6 6 (br, 1H), 3.51 (br, 2H), 3.20-2.92 (m, 4H), 2.29 (s, 3H), 2.13 (br, 2H), 1.65 (br, 2H), 1.29-1.13 (m, 3H).

[0477] Example 115 3-{5-[(1-benzylpiperidin-4-yl)amino]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazine 5-oxazolone 4-methylbenzene-1-sulfonate By following steps 1, 2 and 3 of Example 111, 1-benzylpiperidine-4-amine (86 mg) was used instead of (2-aminoethyl)dimethylamine to obtain the title compound (109 mg).

[0478] MS (m / z): 352.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.13-8.02 (m, 1H), 7.68 (d, 1H), 7.58-7.38 (m, 7H), 7.18-7.06 (m, 3H), 6. 80-6.72 (m, 1H), 4.23 (br, 1H), 3.55 (br, 2H), 2.99 (br, 2H), 2.29 (s, 3H), 2.10 (br, 2H), 1.60 (br, 2H).

[0479] Example 116 3-{5-[(1-ethylpiperidin-4-yl)(methyl)amino]pyridin-2-yl}-4,5-dihydro-1,2, 4-Oxadiazol-5-one 4-methylbenzene-1-sulfonate By following steps 1, 2 and 3 of Example 111, 1-ethyl-N-methylpiperidin-4-amine (64 mg) was used instead of (2-aminoethyl)dimethylamine to obtain the title compound (13 mg).

[0480] MS (m / z): 304.3[M+H] + 1H-NMR (400MHz, DMSO-d6) δ: 8.29 (d, 1H), 7.75 (d, 1H), 7.46 (d, 2H), 7.35 (dd, 1H), 7.10 (d, 2H), 4.16 (br, 1H), 3 .60-3.40 (m, 2H), 3.02 (br, 2H), 2.85 (s, 3H), 2.28 (s, 3H), 2.02-1.89 (m, 2H), 1.88-1.79 (m, 2H), 1.20 (t, 3H).

[0481] Example 117 3-{5-[(1-benzylpiperidin-4-yl)(methyl)amino]pyridin-2-yl}-4,5-dihydro-1,2, 4-Oxadiazol-5-one 4-methylbenzene-1-sulfonate By following steps 1, 2 and 3 of Example 111, 1-benzyl-N-methylpiperidine-4-amine (92 mg) was used instead of (2-aminoethyl)dimethylamine to obtain the title compound (55 mg).

[0482] MS (m / z): 366.4[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.31-8.26 (m, 1H), 7.74 (d, 1H), 7.58-7.38 (m, 7H), 7.38-7.33 (m, 1H), 7.11 (d, 2H), 4.15 (br, 1H), 3.58-3.45 (m, 2H), 3.02 (br, 2H), 2.84 (s, 3H), 2.29 (s, 3H), 1.96 (br, 2H), 1.83 (br, 2H).

[0483] Example 118 3-(5-{4-[2-(pyrrolidone-1-yl)ethyl]piperidin-1-yl}pyridin-2-yl)-4,5-dihydro- 1,2,4-Oxadiazol-5-one 4-methylbenzene-1-sulfonate The mixture of 3-(5-fluoropyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (30 mg), 4-[2-(pyrrolidone-1-yl)ethyl]piperidine (75 mg), 1-methylpyrrolidone-2-one (1 mL), and diisopropylethylamine (0.072 mL) obtained in step 1 of Example 51 was stirred at 150 °C for 2 hours under microwave irradiation. An aqueous solution of 4-methylbenzene-1-sulfonic acid hydrate (252 mg) was added dropwise to adjust the pH to acidic. Purification was performed by silica gel column chromatography to obtain the title compound (50 mg).

[0484] MS (m / z): 344.3[M+H] + 1H-NMR (400MHz, DMSO-d6) δ: 9.37 (br, 1H), 8.39 (d, 1H), 7.75 (d, 1H), 7.47 (d, 2H), 7.44 (d, 1H), 7.11 (d, 2H), 3.99 (d, 2H), 3.52 ( br, 2H), 3.18 (t, 2H), 3.01 (br, 2H), 2.87 (t, 2H), 2.29 (s, 3H), 1.92 (br, 4H), 1.76 (d, 2H), 1.65-1.53 ​​(m, 3H), 1.29-1.15 (m, 2H).

[0485] Example 119 3-(5-{4-[2-(dimethylamino)ethyl]piperidin-1-yl}pyridin-2-yl)-4,5-dihydro- 1,2,4-Oxadiazol-5-one 4-methylbenzene-1-sulfonate By using dimethyl [2-(piperidin-4-yl)ethyl]amine (65 mg) instead of 4-[2-(pyrrolidone-1-yl)ethyl]piperidine according to the method of Example 118, the title compound (60 mg) was obtained.

[0486] MS (m / z): 318.3[M+H] + 1 H-NMR (400MHz, DMSO-d6) δ: 8.39 (d, 1H), 7.75 (d, 1H), 7.47 (d, 2H), 7.44 (d, 1H), 7.11 (d, 2H), 3.98 (d, 2H) , 3.10 (t, 2H), 2.87 (t, 2H), 2.77 (s, 6H), 2.29 (s, 3H), 1.75 (d, 2H), 1.62-1.49 (m, 3H), 1.31-1.15 (m, 2H).

[0487] The structural formulas of the compounds obtained in Examples 1 to 119 are shown in Table 1.

[0488] [Table 1] .

[0489] The following are examples of biological tests on the compounds (test substances) obtained in the embodiments.

[0490] <Experimental Example 1: Evaluation of the inhibitory effect of CUG repeat RNA on the binding of MBNL protein> 1. Preparation of the solution of the substance to be tested The analyte was prepared to a concentration of 10 mM using dimethyl sulfoxide (DMSO, Nacalai Tesque, 13445-74), and then diluted with DMSO to obtain six concentration points: 10000, 3000, 1000, 300, 100, and 10 μM. The solutions were then prepared by 10-fold dilution with RNase-free water (untreated with DEPC) (ThermoFisher SCIENTIFIC, AM9937) to obtain concentrations of 1000, 300, 100, 30, 10, and 1 μM.

[0491] 2. Determination of the inhibitory effect of CUG repeat RNA on the binding of MBNL protein Solutions of the analyte at six concentration points were prepared and added at 2 μL / well to a 384-well plate (PerkinElmer, 6008350) to achieve final concentrations of 100,000, 30,000, 10,000, 3,000, 1,000, and 100 nM, respectively. Then, 40 mM HEPES (Nacalai Tesque, 17547-24), 220 mM KCl (Nacalai Tesque, 28514-75), 20 mM sodium chloride (Nacalai Tesque, 31319-45), 2 mM magnesium chloride hexahydrate (Nacalai Tesque, 20908-65), 4 mM calcium chloride dihydrate (Fujifilm Wako Pure Chemicals, 036-19731), and 0.2% BSA (Nacalai Tesque, 036-19731) were added. Tesque (08587-26), 0.1% Tween (Tokyo Chemical Industry Co., Ltd., T0543-25G), buffer containing 10 mM dithiothreitol (NacalaiTesque, 14112-52), and synthetic RNA (Sigma) with a CUG 12-repetition sequence were mixed to a final concentration of 5 nM and MBNL protein to a final concentration of 150 nM, and added at 14 μL / well. After incubation at room temperature for 30 minutes, donor-acceptor beads from the AlphaScreen Histidine Detection Kit (PerkinElmer, 6760619M) were added to a final concentration of 5 μg / mL at 4 μL / well. After incubation at room temperature for 1.5 hours, fluorescence intensity was measured using Envision (PerkinElmer) at an excitation wavelength of 680 nm and an absorption wavelength of 520-620 nm. The experiment was repeated.

[0492] 3. Analysis of Measurement Results Set the maximum inhibition rate of each analyte to 100% and the minimum inhibition rate to 0%, then calculate the inhibition rate of the analyte. The IC50 of the analyte is then calculated. 50 The values ​​(50% inhibition concentration) were calculated using logistic regression analysis. The determination results of the compounds obtained in each example are shown in Tables 2–4 below.

[0493] [Table 2] .

[0494] [Table 3] .

[0495] [Table 4] .

[0496] <Experimental Example 2: In vivo pharmacodynamic study using a myotonic dystrophy type 1 model> 1. Preparation of the drug solution for the test substance Weigh the test substance and suspend it in 0.5% methylcellulose (Shin-Etsu Chemical Industry) + 99.5% Otsuka distilled water (Otsuka Pharmaceutical Factory) to prepare a test substance administration solution with a concentration of 10 mg / mL.

[0497] 2. Making animal models The animals used were FVB / N-Tg (HSA*LR) 20bCath / J (6-week-old males) used as a model of myotonic dystrophy. LR The mice were transgenic animals with 220 CTG repeat sequences inserted downstream of the hACTA gene, which expressed mRNA containing CTG repeats in skeletal muscle, thereby exhibiting DM1-like symptoms (Non-Patent Literature 7). FVB / Njcl (6-week-old males) were used as healthy animals.

[0498] 3. Research on the effect of splicing improvement The test substance was administered orally twice daily for 4 days. On day 5 of administration, the individual was euthanized, and the quadriceps femoris muscle was harvested. Total RNA was extracted using Qiazol Reagent (Qiagen, 79306) and the Maxwell RSC Simple RNA Tissue Kit (Promega, A1340). cDNA was then prepared using the SuperScript IV First Strand Synthesis System (Invitrogen, 18091050). RT-PCR was performed using the cDNA with either Clcn1 exon 7a or CACNA1S exon 29 RT primers. The RT-PCR products were electrophoresed using MultiNA (Shimadzu Corporation), and the normal and abnormal PCR products were quantified separately to calculate the proportion of normal PCR products.

[0499] <Clcn1 exon 7a RT primer> Fw:TGAAGGAATACCTCACACTCAAGG Rv:CACGGAACACAAAGGCACTG <CACNA1S exon 29 RT primer> Fw:GAGATCCTTGGAATGTGTTTGACTTCCT Rv:GGTTCAGCAGCTTGACCAGTCTCAT.

[0500] 4. Analysis of Measurement Results The shear improvement rate was calculated based on the shear ratios of the FVB / N-Tg(HSA*LR)20bCath / J medium administration group and the FVB / Njcl group (Non-Patent Literature 8). The experimental results are shown in Table 5.

[0501] [Table 5] .

Claims

1. A compound of general formula (1) or a pharmaceutically acceptable salt thereof, or a solvate thereof: [Chemistry 1] In the formula, X 1 X 2 and X 3 For any of the following combinations: (a) X 1 X 2 and X 3 For -CH=、(b)X 1 For -N=, X 2 -CH=, X 3 For -CH=, or (c)X 1 -CH=, X 2 -CH=, X 3 For -N=, A represents -O-, -S-, -NR-, or piperidinediyl, where R represents a hydrogen atom or a C1-C3 alkyl group. B represents a single bond, a C1-C5 alkylene group that can be substituted with a hydroxyl group, or -Y. 1 -NY 2 -Y 3 -, Y 1 and Y 3 Each independently represents a C1-C3 alkylene group, Y 2 Indicates a hydrogen atom or a C1-C3 alkyl group. C represents a substituted or unsubstituted aryl group, a substituted or unsubstituted nitrogen-containing heterocyclic group, or a dialkylamino group. in, At least one of B and C contains more than one nitrogen atom.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein, A is -O-.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, or a solvation thereof, wherein, B is a single bond or a C1-C5 alkylene bond.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, or a solvation thereof, wherein, C is a substituted or unsubstituted nitrogen-containing heterocyclic group.

5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a solvation thereof, wherein, C is a substituted or unsubstituted piperidinyl, a substituted or unsubstituted piperazine, or a substituted or unsubstituted pyrroleyl.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, or a solvation thereof, wherein, C is a nitrogen-containing heterocyclic group substituted with an alkyl, benzyl, or acyl group, or an unsubstituted nitrogen-containing heterocyclic group.

7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a solvation thereof, wherein, X 1 X 2 and X 3 For (a)X 1 X 2 and X 3 For combinations of -CH=, A represents -O-, B represents a single bond or a C1-C5 alkylene bond. C represents a substituted or unsubstituted nitrogen-containing heterocyclic group.

8. A compound or a pharmaceutically acceptable salt thereof, or a solvation thereof, wherein, The compounds are selected from the group consisting of compounds (1) to (104) and (107) to (119) below: (1) 3-{5-[(1-ethylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (2) 3-(5-{[(3R)-1-ethylpiperidin-3-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (3) 3-(5-{[(3S)-1-ethylpiperidin-3-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (4) 3-{5-[(1-benzylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (5) 3-(5-{2-[benzyl(methyl)amino]ethoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (6) 3-{5-[2-(4-acetylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (7) 3-{5-[3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (8) 3-{5-[3-(pyrrolidone-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (9) 3-{5-[2-(pyrrolidone-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (10) 3-{5-[2-(4-benzylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (11) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid phenyl ester (12) 3-{5-[2-(piperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (13) 3-{5-[2-(4-phenoxypiperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (14) 3-{5-[(1-cyclopropanecarbonylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (15) 3-{5-[(1-propylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (16) 3-(5-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (17) 3-{5-[(1-propylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (18) 3-{5-[2-(2,3-dihydro-1H-isoindol-2-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (19) 3-{5-[2-(1,2,3,4-tetrahydroisoquinolin-2-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (20) 4-({[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}methyl)piperidine-1-carboxylic acid ethyl ester (21) 3-(5-{3-[4-(2-fluorophenyl)piperazin-1-yl]propoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (22) 3-{5-[2-(4-phenylpiperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (23) 3-{5-[3-(piperidin-1-yl)propoxy]pyrimidin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (24) 3-{6-[3-(piperidin-1-yl)propoxy]pyridazin-3-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (25) 3-(5-{[3-(piperidin-1-yl)propyl]thioalkyl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (26) 3-(5-{[3-(pyrrolidone-1-yl)propyl]thioalkyl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (27) 3-(5-{[3-(azacycloheptane-1-yl)propyl]thioalkyl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (28) 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}piperidine-1-carboxylic acid phenyl ester (29) 4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}piperidine-1-carboxylic acid ethyl ester (30) 3-{5-[(1-ethylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (31) 3-{5-[(1-butylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (32) 3-{5-[(1-pentylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (33) 3-(5-{[1-(cyclobutylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (34) 3-(5-{[1-(propane-2-yl)piperidin-4-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (35) 3-{5-[(1-butylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (36) 3-(5-{[1-(cyclopropylmethyl)piperidin-4-yl]methoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (37) 3-{5-[(1-benzylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (38) 3-[5-({1-[(2-ethylphenyl)methyl]piperidin-4-yl}methoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (39) 3-{5-[(1-{[2-(trifluoromethyl)phenyl]methyl}piperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (40) 3-[5-({1-[(3-fluorophenyl)methyl]piperidin-4-yl}methoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (41) 3-[5-({1-[(3-bromophenyl)methyl]piperidin-4-yl}methoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (42) 3-{5-[(1-acetylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (43) 3-{5-[(1-propionylpiperidin-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (44) 4-({[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}methyl)piperidine-1-carboxylic acid methyl ester (45) 4-({[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}methyl)piperidin-1-propane-2-yl ester) (46) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid methyl ester (47) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid ethyl ester (48) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid propyl ester (49) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-propane-2-yl ester (50) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid benzyl ester (51) 3-{5-[3-(azacycloheptane-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (52) 3-{5-[2-(azacycloheptane-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (53) 3-{5-[2-(4-methoxypiperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (54) 3-{5-[2-(3-methoxypiperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (55) 3-[5-(2-{7-azaspiro[4.5]decane-7-yl}ethoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (56) 3-[5-(2-{9-oxa-2-azaspiro[5.5]undecane-2-yl}ethoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (57) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid tert-butyl ester (58) 3-{5-[2-(piperazin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (59) 3-{5-[2-hydroxy-3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (60) 3-{5-[3-(4-hydroxypiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (61) 3-{5-[3-(3-hydroxypiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (62) 3-{5-[3-(morpholin-4-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (63) 3-{5-[3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (64) 3-[5-(3-{1,4-dioxa-8-azaspiro[4.5]decane-8-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (65) 1-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl)piperidin-4-one (66) 3-{5-[3-(3-fluoropiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (67) 3-{5-[3-(4-methylpiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (68) 3-{5-[3-(4-methoxypiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (69) 3-(5-{3-[(trans)3,4-dihydroxypiperidin-1-yl]propoxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (70) 3-{5-[3-(4,4-difluoropiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (71) 3-{5-[3-(4-fluoro-4-methylpiperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (72) 3-{5-[3-(4-acetylpiperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (73) 4-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl)piperazine-1-carboxylic acid methyl ester (74) 3-{5-[3-(piperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (75) 3-{5-[3-(4-benzylpiperazin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (76) 3-[5-(3-{3-azabicyclo[3.1.0]hexane-3-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (77) 3-[5-(3-{octahydrocyclopentanol[c]pyrrolo-2-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (78) 3-[5-(3-{7-azaspiro[4.5]decane-7-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (79) 3-[5-(3-{2-oxa-8-azaspiro[4.5]decane-8-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (80) 3-[5-(3-{9-oxa-2-azaspiro[5.5]undecane-2-yl}propoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (81) 1-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl)pyridine-1-onium 4-methylbenzene-1-sulfonate (82) 3-{5-[(5-methyl-1,3-oxazol-4-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (83) 3-{5-[(1,3-thiazolyl-2-yl)methoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (84) 3-{5-[3-(pyridin-3-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (85) 1-(3-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}propyl)piperidin-2-one (86) 3-{5-[2-methyl-3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (87) 3-{5-[2-(dimethylamino)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (88) 3-{5-[3-(dimethylamino)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (89) 3-{5-[4-(dimethylamino)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (90) 3-{5-[4-(piperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (91) 3-{5-[4-(azacycloheptane-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (92) 3-{5-[4-(pyrrolidone-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (93) 3-{5-[4-(3-hydroxypiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (94) 3-{5-[4-(morpholin-4-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (95) 3-{5-[4-(4-fluoropiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (96) 3-{5-[4-(4,4-dimethylpiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (97) 3-{5-[4-(3-hydroxy-3-methylpiperidin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (98) 3-[5-(4-{7-azaspiro[4.5]decane-7-yl}butoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (99) 3-[5-(4-{9-oxa-2-azaspiro[5.5]undecane-2-yl}butoxy)pyridin-2-yl]-4,5-dihydro-1,2,4-oxadiazol-5-one (100) 4-(4-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}butyl)piperazine-1-carboxylic acid methyl ester (101) 3-{5-[4-(4-acetylpiperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (102) 3-{5-[4-(piperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (103) 3-{5-[4-(4-benzylpiperazin-1-yl)butoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (104) 3-(5-{[5-(piperidin-1-yl)pentyl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (107) 3-(5-{[2-(pyridin-4-yl)ethyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (108) 3-(5-{[3-(piperidin-1-yl)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (109) 3-(5-{[(1-ethylpiperidin-4-yl)methyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (110) 3-(5-{methyl[3-(piperidin-1-yl)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (111) 3-(5-{[2-(dimethylamino)ethyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (112) 3-(5-{[3-(dimethylamino)propyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (113) 3-(5-{[4-(dimethylamino)butyl]amino}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (114) 3-{5-[(1-ethylpiperidin-4-yl)amino]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (115) 3-{5-[(1-benzylpiperidin-4-yl)amino]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (116) 3-{5-[(1-ethylpiperidin-4-yl)(methyl)amino]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (117) 3-{5-[(1-benzylpiperidin-4-yl)(methyl)amino]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (118) 3-(5-{4-[2-(pyrrolidone-1-yl)ethyl]piperidin-1-yl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one (119) 3-(5-{4-[2-(dimethylamino)ethyl]piperidin-1-yl}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one.

9. A compound or a pharmaceutically acceptable salt thereof, or a solvation thereof, wherein, The compounds are selected from the group consisting of compounds listed in (7), (11), (12), (15) and (16) below: (7) 3-{5-[3-(piperidin-1-yl)propoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (11) 4-(2-{[6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl]oxy}ethyl)piperazine-1-carboxylic acid phenyl ester (12) 3-{5-[2-(piperidin-1-yl)ethoxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (15) 3-{5-[(1-propylpiperidin-4-yl)oxy]pyridin-2-yl}-4,5-dihydro-1,2,4-oxadiazol-5-one (16) 3-(5-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}pyridin-2-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one.

10. A pharmaceutical composition comprising, as an active ingredient, any one of claims 1 to 9, a pharmaceutically acceptable salt thereof, or a solvation thereof.

11. A treatment for myotonic dystrophy type 1, comprising the compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.

12. Use of the compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, or a solvate thereof, in the manufacture of a therapeutic agent for myotonic dystrophy type 1.

13. A binding inhibitor that inhibits the binding of CUG repeat RNA to MBNL protein, and comprising, as an active ingredient, any one of claims 1 to 9, a pharmaceutically acceptable salt thereof, or a solvate thereof.